UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549


FORM 10-Q


þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended September 30, 2008.


¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ______to _________.


Commission file number: 00-51354


AE BIOFUELS, INC.

(Exact name of registrant as specified in its charter)


Nevada

26-1407544

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer Identification No.)


20400 Stevens Creek Blvd., Suite 700

Cupertino, CA 95014

(Address of principal executive offices)


(408) 213-0940

(Registrant's telephone number, including area code)


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer        ¨

 

Accelerated filer ¨

Non-accelerated filer          ¨

 

Smaller reporting company þ


Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ


The number of shares outstanding of the registrant’s common stock as of October 28, 2008 was 85,549,940 shares.

 

 






AE BIOFUELS, INC.

FORM 10-Q  

Quarter Ended September 30, 2008


 

 

Page

 

 

 

INDEX

 

 

PART I— FINANCIAL INFORMATION

 

 

Item 1.

Financial Statements

 

 

 

Consolidated Balance Sheets as of  September 30, 2008 and December 31, 2007

 

 2

 

Consolidated Statements of Operations for Three and Nine Months Ended September 30, 2008 and 2007 and for the period from November 29, 2005 (inception) to September 30, 2008

 

 3

 

Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2008 and 2007 and for the period from November 29, 2005 (inception) to September 30, 2008

 

 4

 

Notes to Consolidated Financial Statements

 

5

 

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

20

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

 

26

Item 4T.

Controls and Procedures

 

27

 

 

 

 

PART II— OTHER INFORMATION

 

 

Item 1.

Legal Proceedings

 

29

Item 1A.

Risk Factors

 

29

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

 

30

Item 3.

Defaults Upon Senior Securities

 

30

Item 4.

Submission of Matters to a Vote of Security Holders

 

30

Item 5.

Other Information

 

30

Item 6.

Exhibits

 

30

SIGNATURES

 

31




1



PART I - FINANCIAL INFORMATION


Item 1 - Financial Statements


AE BIOFUELS, INC.

(A Development Stage Company)

CONSOLIDATED BALANCE SHEETS


 

 

September 30,

2008

 

December 31,

2007

 

 

 

(Unaudited)

 

 

 

Assets

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

591,718

 

$

720,402

 

Marketable securities

 

 

-

 

 

2,635,892

 

Accounts receivable

 

 

-

 

 

3,447,039

 

Accounts receivable - related party

 

 

-

 

 

6,127,727

 

Inventories

 

 

1,254,008

 

 

-

 

Prepaid expenses

 

 

142,533

 

 

58,872

 

Other current assets

 

 

334,162

 

 

674,235

 

Total current assets

 

 

2,322,421

 

 

13,664,167

 

 

 

 

 

 

 

 

 

Property, plant and equipment, net

 

 

21,926,418

 

 

19,585,087

 

Intangible assets

 

 

 83,334

 

 

233,334

 

Other assets

 

 

483,229

 

 

68,488

 

Total assets  

 

$

24,815,402

 

$

33,551,076

 

 

 

 

 

 

 

 

 

Liabilities and stockholders' equity

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

$

1,080,066

 

$

9,985,639

 

Income taxes payable

 

 

6,092

 

 

36,750

 

Short term borrowings, net of discount

 

 

4,173,437

 

 

-

 

Other current liabilities

 

 

3,673,760

 

 

-

 

Current portion of long-term debt

 

 

538,213

 

 

-

 

Total current liabilities

 

 

9,471,568

 

 

10,022,389

 

 

 

 

 

 

 

 

 

Long-term debt, net of discount

 

 

3,633,709

 

 

-

 

Long-term debt (related party)

 

 

1,300,495

 

 

-

 

 

 

 

 

 

 

 

 

Commitments and contingencies (Notes 6, 7, 8, 13, 14, 15, 17 and 18)

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

 

Series B preferred stock, $0.001 par value – 7,235,402 authorized; 5,533,821 and 6,487,491 shares issued and outstanding, respectively (aggregate liquidation preference of $16,601,463 and  $19,462,473)

 

 

 5,533

 

 

6,487

 

Common Stock, $0.001 par value - 400,000,000 authorized; 85,532,020 and 84,557,462 shares issued and outstanding, respectively

 

 

 85,531

 

 

84,557

 

Additional paid-in capital

 

 

36,283,215

 

 

33,707,953

 

Deficit accumulated during the development stage

 

 

 (25,152,218

)

 

(11,995,395

)

Accumulated other comprehensive (loss) income

 

 

(812,431

)

 

1,725,085

 

Total stockholders' equity

 

 

10,409,630

 

 

23,528,687

 

 

 

 

    

 

 

   

 

Total liabilities and stockholders' equity  

 

$

24,815,402

 

$

33,551,076

 


The accompanying notes are an integral part of the financial statements



2



AE BIOFUELS, INC.

(A Development Stage Company)

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)


 

 

For the three months ended

 

For the nine months ended

 

Period from

November 29,

2005 (Date of

Inception) to

September 30,

2008

 

 

 

September 30,

2008

 

September 30,

2007

 

September 30,

2008

 

September 30,

2007

 

 

 

 

 

 

 

 


 

 

 

 

 

 

 

 

 

 

Sales

 

$

-

 

$

-

 

$

-

 

$

-

 

$

744,450

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold (inventory provision)

 

 

952,028

 

 

-

 

 

952,028

 

 

-

 

 

1,687,028

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

(952,028

)

 

-

 

 

(952,028

 

-

 

 

(942,578

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

316,402

 

 

66,583

 

 

828,458

 

 

186,583

 

 

1,086,219

 

General and administrative expenses

 

 

1,921,372

 

 

8,545,658

 

 

7,540,720

 

 

11,815,792

 

 

28,355,186

 

Loss on forward purchase commitments

 

 

532,500

 

 

-

 

 

532,500

 

 

-

 

 

532,500

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating loss

 

 

(3,722,302

)

 

(8,612,241

)

 

(9,853,706

)

 

(12,002,375

)

 

(30,916,483

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

58

 

 

69,150

 

 

32,544

 

 

20,259

 

 

130,294

 

Interest expense

 

 

-

 

 

-

 

 

(253,020

)

 

-

 

 

(253,020

)

Other income, net of expenses

 

 

71,160

 

 

138,036

 

 

113,321

 

 

154,796

 

 

301,637

 

Gain from dissolution of joint venture

 

 

-

 

 

8,206,446

 

 

-

 

 

9,061,141

 

 

9,061,141

 

Gain on foreign currency exchange

 

 

-

 

 

492,659

 

 

-

 

 

544,775

 

 

497,954

 

Shareholder agreement cancellation payment

 

 

-

 

 

-

 

 

(900,000

)

 

-

 

 

(900,000

)

Registration rights obligations

 

 

-

 

 

-

 

 

(2,274,402

)

 

-

 

 

(2,274,402

)

Income (loss) related to 50/50 joint venture

 

 

-

 

 

(87,866

)

 

-

 

 

67,670

 

 

182,923

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income (loss) before income taxes

 

 

(3,651,084

)

 

206,184

 

 

(13,135,263

)

 

(2,153,734

)

 

(24,169,956

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income taxes

 

 

-

 

 

(48,129

)

 

(21,560

)

 

(48,129

)

 

(100,145

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$

(3,651,084

)

$

158,055

 

$

(13,156,823

)

$

(2,201,863

)

$

(24,270,101

)

Other comprehensive income (loss), net of tax

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustments

 

 

1,090,458

 

 

(3,259,939

)

 

2,537,516

 

 

(1,395,876

)

 

(812,431

)

Comprehensive loss, net of taxes

 

$

(2,560,626

)

$

(3,101,884

)

$

(10,619,307

)

$

(3,597,739

)

$

(25,082,532

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss per common share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

$

(0.04

)

$

 -

 

$

(0.16

)

$

(0.03

)

$

(0.32

)

Weighted average shares outstanding

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

 

84,935,737

 

 

73,422,681

 

 

84,459,343

 

 

73,274,586

 

 

75,697,648

 


The accompanying notes are an integral part of the financial statements



3



AE BIOFUELS, INC.

(A Development Stage Company)


CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

 

 




For the nine months ended

 

Period from

November 29,

2005 (Date of

Inception) to

September 30,

2008

 

 

 

September 30,

2008

 

September 30,

2007

 

 

Operating activities:

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(13,156,823

)

$

(2,201,863

)

$

(24,270,101

)

Adjustments to reconcile net loss to

 

 

 

 

 

 

 

 

 

 

net cash used in operating activities:

 

 

 

 

 

 

 

 

 

 

Stock based compensation

 

 

1,776,882

 

 

862,537

 

 

3,414,841

 

Expired land options

 

 

124,536

 

 

248,340

 

 

569,660

 

Amortization and depreciation

 

 

168,284

 

 

33,437

 

 

238,059

 

Inventory provision

 

 

952.028

 

 

 

 

 

952,028

 

Loss on forward purchase contract

 

 

532,500

 

 

-

 

 

532,500

 

Amortization of debt discount

 

 

495,942

 

 

-

 

 

495,942

 

Registration rights obligation

 

 

2,274,402

 

 

-

 

 

2,274,402

 

Gain on sale of subsidiary

 

 

-

 

 

(881,481

)

 

(854,695

)

Loss on impairment of assets

 

 

-

 

 

5,114,236

 

 

5,114,236

 

Gain on dissolution of joint venture

 

 

-

 

 

(8,206,446

 )

 

(8,206,446

)

Gains on forward currency contracts

 

 

-

 

 

-

 

 

(436,154

)

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

 

 

Accounts receivable

 

 

9,490,481

 

 

-

 

 

557,206

 

Inventory

 

 

(2,280,540

)

 

-

 

 

(2,280,540

)

Prepaid expenses

 

 

(114,465

)

 

258,869

 

 

(175,262

)

Other assets

 

 

(1,778,139

)

 

(1,019,064

)

 

(1,361,372

)

Accounts payable

 

 

(8,637,365

)

 

(170,469

)

 

737,567

 

Other liabilities

 

 

2,882,172

 

 

85,087

 

 

2,825,141

 

Income taxes payable

 

 

(29,775

)

 

-

 

 

6,973

 

Net cash used in operating activities

 

 

(7,299,880

)

 

(5,876,817

)

 

(19,866,014

)

 

 

 

 

 

 

 

 

 

 

 

Investing activities:

 

 

 

 

 

 

 

 

 

 

Purchases of property, plant and equipment

 

 

(5,918,939

)

 

(10,459,960

)

 

(32,760,043

)

Purchases of marketable securities

 

 

-

 

 

-

 

 

(2,459,292

)

Sales of marketable securities

 

 

2,568,216

 

 

-

 

 

2,568,216

 

Cash payments to settle forward contracts

 

 

(198,213

)

 

-

 

 

(198,213

)

Cash restricted by letter of credit

 

 

500,000

 

 

 

 

 

-

 

Cash payment to settle forward purchase contract

 

 

 

 

 

 

 

 

 

 

Purchase of Marwich II, Ltd., net of losses

 

 

-

 

 

-

 

 

(662,406

)

Exchange rate contract settlements

 

 

-

 

 

 

 

 

(193,399

)

Additions to other assets and intangibles

 

 

-

 

 

-

 

 

(1,073,872

)

Refund of property expenditures

 

 

-

 

 

2,775,000

 

 

2,775,000

 

Return of cash from dissolution of joint venture

 

 

-

 

 

8,206,446

 

 

8,206,446

 

Sale of Wahoo facility

 

 

-

 

 

2,000,000

 

 

2,000,000

 

Net cash provided by (used in) investing activities

 

 

(3,048,936

)

 

2,521,486

 

 

(21,797,562

)

 

 

 

 

 

 

 

 

 

 

 

Financing activities:

 

 

 

 

 

 

 

 

 

 

Proceeds from short-term borrowings

 

 

5,662,786

 

 

 

 

 

5,662,786

 

Payments of short-term borrowings

 

 

-

 

 

(1,250,000

)

 

 -

 

Proceeds from long-term debt

 

 

4,469,547

 

 

 

 

 

4,719,547

 

Payments on long-term debt

 

 

-

 

 

(218,311

)

 

(250,000

)

Proceeds from settlement

 

 

-

 

 

200,000

 

 

200,000

 

Refund of investment

 

 

-

 

 

(90,000

)

 

(90,000

)

Proceeds from sale of preferred stock, net of offering costs

 

 

910

 

 

10,056,354

 

 

31,911,422

 

Net cash provided by financing activities

 

 

10,133,243

 

 

8,698,043

 

 

42,153,755

 

Effect of exchange rate fluctuations on cash and cash equivalents

 

 

86,890

 

 

-

 

 

101,539

 

Net (decrease) increase in cash and cash equivalents for period

 

 

(128,684

)

 

5,342,712

 

 

591,718

 

Cash and cash equivalents, beginning of period

 

 

720,402

 

 

1,212,934

 

 

-

 

Cash and cash equivalents, end of period

 

$

591,718

 

$

6,555,646

 

$

591,718

 

 

The accompanying notes are an integral part of the financial statements



4




AE BIOFUELS, INC.

(A Development Stage Company)


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)




1.

Nature of Activities and Summary of Significant Accounting Policies.

Nature of Activities . These consolidated financial statements include the accounts of AE Biofuels, Inc., a Nevada corporation, and its wholly-owned subsidiaries, American Ethanol, Inc. (“American”), a Nevada corporation and its subsidiaries; Sutton Ethanol, LLC (“Sutton”), a Nebraska limited liability company; Illinois Valley Ethanol, LLC (“Illinois Valley”), an Illinois limited liability company; Biofuels Marketing, Inc., a Delaware corporation; International Biodiesel, Inc., a Nevada corporation and its subsidiaries International Biofuels, Ltd, a Mauritius corporation and its subsidiary Universal Biofuels Private Ltd., an India company; Danville Ethanol, Inc., an Illinois corporation; Energy Enzymes Inc., a Delaware corporation, and AE Biofuels Americas, a Delaware corporation collectively, (“AE Biofuels” or “the Company”).

The Company’s purpose is to develop, acquire, construct, operate and sell fuel grade ethanol and biodiesel from next-generation technology ethanol and biodiesel production facilities. The Company does not expect to generate significant revenue until its plants are constructed and operational, or operational plants have been acquired. Since inception, the Company has engaged in (i) raising funds through the sale of stock, (ii) purchasing land or options to purchase land for development of ethanol plants in the United States, (iii) selling an ethanol plant site in Wahoo, Nebraska, (iv) receiving permits for ethanol plant sites in Nebraska and Illinois, (v) developing, drafting and submitting three patents on cellulosic ethanol production technology, (vi) constructing a biodiesel manufacturing facility in Kakinada, India through International Biodiesel, Inc. and Universal Biofuels Private, Ltd., a Mauritius corporation, (vii) starting ground work for an ethanol facility in Sutton, Nebraska, (viii) constructing a glycerin refining and vegetable oil pre-treatment facility at the Kakinada plant, and (ix) constructing a cellulosic ethanol commercial demonstration facility in Butte, Montana.

AE Biofuels was originally formed in California on September 12, 2001 as Great Valley Ventures LLC, however, no operating agreement was adopted and no capital was contributed until November 29, 2005. Between September 2001 and November 2005, the Company had no operations and engaged in no activities. From November 2005 through December 2005, the Company commenced development activities with the addition of key advisors, management, and additional founding shareholders. On January 12, 2006, the Company was renamed American Ethanol, LLC. On February 23, 2006, American Ethanol, LLC merged into American Ethanol, Inc., a Nevada corporation.

On June 23, 2006, American Ethanol acquired 88.3% of the outstanding common stock of Marwich II, Ltd. (“Marwich”). Marwich was a shell company with no operations. On December 7, 2007, American Ethanol merged with and into Marwich and (i) each issued and outstanding share of American Ethanol common stock (including common stock issued upon conversion of American Ethanol Series A Preferred Stock, which automatically converted into two common shares for each share of Series A Preferred Stock immediately prior to the closing of the Merger) and Series B Preferred Stock (also convertible into common stock at the holders discretion) converted into common stock and Series B Preferred Stock, respectively, of Marwich, and (ii) each issued and outstanding warrant and/or option exercisable for common stock or Series B preferred stock of American Ethanol was assumed and converted into a warrant and/or option exercisable for common stock or Series B preferred stock of Marwich. Marwich then changed its name to AE Biofuels, Inc.

Basis of Presentation and Consolidation . The consolidated financial statements include the accounts of the Company and its majority -owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The accompanying consolidated balance sheets as of September 30, 2008, the consolidated statements of operations for the three and nine months ended September 30, 2008 and 2007, and the consolidated statements of cash flows for the nine months ended September 30, 2008 and 2007 are unaudited. The consolidated balance sheet as of December 31, 2007 was derived from the 2007 audited consolidated financial statements and notes thereto. The consolidated financial statements in this report should be read in conjunction with the 2007 audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2007.  As of September 30, 2008 the Company is a development stage enterprise and presents its statements in accordance with SFAS No. 7, “ Accounting and Reporting by Development Stage Enterprises ”.  The Company expects to commence its principal operations in the fourth quarter of 2008.



5




AE BIOFUELS, INC.

(A Development Stage Company)


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)




1.

Nature of Activities and Summary of Significant Accounting Policies (contd.).

The accompanying unaudited interim consolidated financial statements as of  September 30, 2008 and 2007 and for the three and nine months ended September 30, 2008 and 2007 have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations.

In the opinion of management, the unaudited interim consolidated financial statements for the three and nine months ended September 30, 2008 and 2007 have been prepared on the same basis as the audited consolidated statements as of December 31, 2007 and reflect all adjustments, consisting primarily of normal recurring adjustments, necessary for the fair presentation of its statement of financial position, results of operations and cash flows. The results of operations for the three and nine months ended September 30, 2008 are not necessarily indicative of the operating results for any subsequent quarter, for the full fiscal year or any future periods.

Use of Estimates . The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of expenses during the reporting period. Significant estimates, assumptions and judgments made by management include the determination of impairment of long-lived assets, the valuation of equity instruments such as options and warrants, and the accrual for the payments under the Company's registration rights agreement with certain of its shareholders and management’s judgment about contingent liabilities. Management believes that the estimates and judgments upon which they rely are reasonable based upon information available to them at the time that these estimates and judgments are made. To the extent there are material differences between these estimates and actual results, the Company’s consolidated financial statements will be affected.

Fair Value of Financial Instruments. Our fair value instruments that require remeasurement, primarily marketable securities, are valued by the institution that holds the instruments. Due to the nature of these instruments, which are essentially time deposits, whose original maturity was more than 90 days and could not be classified as cash equivalents. There is little risk of variances between the reported basis by the holding institution and the fair value.  At September 30, 2008, we had one forward inventory purchase contract with a full delivery commitment of $1,492,500 that had been net settled for a fixed amount, and is valued at the fixed amount of the payment due under the terms of the contract.

Reclassifications.    Certain prior year amounts were reclassified to conform to the current year presentation. These reclassifications had no impact on previously reported net loss or deficit accumulated during the development stage.

Revenue Recognition . The Company recognizes revenue when products are shipped and services are rendered, the price is fixed or determinable and collection is reasonably assured. To date, the Company’s revenues have been negligible.

Cost of Goods Sold . Cost of goods sold include those costs directly associated with the production of revenues., such as raw material purchases, factory overhead, and other direct production costs.  For the three months ended September 30, 2008, cost of goods sold consists of a lower of cost or market adjustment taken against inventory.

General and Administrative . General and Administrative expenses include those costs associated with the general operations of our business such as: compensation, rent, consultants, travel related to executive, legal and financial functions.

Cash and Cash Equivalents . The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company maintains cash balances at various financial institutions domestically and abroad.  Domestic accounts are insured by the FDIC.  The Company’s accounts at these institutions may exceed federally insured limits.  The Company has not experienced any losses in such accounts.

Marketable Securities. The Company’s short-term investments consistes primarily of short term time deposits in India banks, which represented funds available for plant completion and current operations. In accordance with Statement of Financial Accounting Standards (“SFAS”) No. 115, Accounting for Certain Investments in Debt and Equity Securitie s, these short-term investments were classified as available-for-sale and were carried at fair market value. These securities had stated maturities beyond three months but were priced and traded as short-term instruments. Available-for-sale securities are marked-to-market based on quoted market values of the securities, with the unrealized gains and losses, net of tax, reported as a component of accumulated other comprehensive income (loss). Realized gains and losses on sales of available-for-sale securities are computed based upon the initial cost adjusted for any other-than-temporary declines in fair value. The cost of investments sold is determined on the specific identification method. The Company did not have any marketable securities at September 30, 2008.



6




AE BIOFUELS, INC.

(A Development Stage Company)


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)




1.

Nature of Activities and Summary of Significant Accounting Policies (contd.).

Accounts Receivable . Accounts receivable consist of commodities purchased and resold either secured by letters of credit or made to large credit worthy customers.  Peripheral or incidental purchases and subsequent sales of commodities are recorded as net other income.

Inventories . Inventories are stated at the lower of cost, using the first-in and first-out (FIFO) method, or market.

Property, Plant and Equipment . Property, plant and equipment are carried at cost less accumulated depreciation after assets are placed in service and are comprised primarily of land acquired for development of production facilities, and the biodiesel plant in India. The estimated useful life of this plant is expected to be 20 years, once placed in service. The estimated useful life for office equipment and computers is three years and the useful life of machinery and equipment is seven years. Depreciation is provided using the straight line method over the useful life of the assets.

Intangible Assets. Intangible assets are carried at initial fair value less accumulated amortization over the estimated useful life. Amortization is computed over the estimated useful lives of the underlying assets using a method that reflects their utilization pattern.

Stock Splits . On February 28, 2006 and May 18, 2006, the Company’s board of directors declared a two-for-one stock split. All share amounts have been retroactively adjusted to reflect the stock splits.

Research and Development. Research and development costs are expensed as incurred, unless they have alternative future uses to the Company.

Income Taxes.     The Company recognizes income taxes in accordance with Statement of Financial Accounting Standard No. 109, “Accounting for Income Taxes” (“SFAS 109”), using an asset and liability approach. This approach requires the recognition of taxes payable or refundable for the current year and deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s consolidated financial statements or tax returns. The measurement of current and deferred taxes is based on provisions of enacted tax law.

SFAS 109 provides for recognition of deferred tax assets if the realization of such assets is more likely than not to occur. Otherwise, a valuation allowance is established for the deferred tax assets which may not be realized. As of December 31, 2007, the Company recorded a full valuation allowance against its net deferred tax assets due to operating losses incurred since inception. Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets were fully offset by a valuation allowance.

The Company is subject to income tax audits by the respective tax authorities in all of the jurisdictions in which it operates. The determination of tax liabilities in each of these jurisdictions requires the interpretation and application of complex and sometimes uncertain tax laws and regulations. The recognition and measurement of current taxes payable or refundable and deferred tax assets and liabilities requires that the Company make certain estimates and judgments. Changes to these estimates or a change in judgment may have a material impact on the Company’s tax provision in a future period.

Effective January 1, 2007, the Company adopted FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes - an interpretation on FASB Statement No. 109” ("FIN 48"), which requires a more-likely-than-not threshold for financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. The Company records a liability for the difference between the benefit recognized and measured pursuant to FIN 48 and the tax position taken or expected to be taken on its tax return. To the extent that the Company’s assessment of such tax position changes, the change in estimate is recorded in the period in which the determination is made. With the adoption of FIN 48, the Company also began reporting tax-related interest and penalties as a component of income tax expense.

Long-Lived Assets. The Company evaluates the recoverability of long-lived assets with finite lives in accordance with Statement of Financial Accounting Standards No. 144, "Accounting for the Impairment or Disposal of Long- Lived Assets" (“SFAS 144”), which requires recognition of impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable based on estimated undiscounted cash flows, the impairment loss would be measured as the difference between the carrying amount of the assets and its fair value based on the present value of estimated future cash flows.



7




AE BIOFUELS, INC.

(A Development Stage Company)


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)




1.

Nature of Activities and Summary of Significant Accounting Policies (contd.).

Basic and Diluted Net Loss per Share.   Basic loss per share is computed by dividing loss attributable to common shareholders by the weighted average number of common shares outstanding for the period, net of shares subject to repurchase. Diluted loss per share reflects the dilution of common stock equivalents such as options, convertible preferred stock and warrants to the extent the impact is dilutive. As the Company incurred net losses for the three and nine month periods ended September 30, 2008 and 2007 and on a cumulative basis, potentially dilutive securities have been excluded from the diluted net loss per share computations as their effect would be anti-dilutive.

The following table shows the  weighted-average number of potentially dilutive shares excluded from the diluted net loss per share calculation for the three months ended September 30, 2008 and 2007 and on a cumulative basis:

 

For the three months ended September 30, 2007

 

For the three months ended  September 30, 2008

 

Period from November 29, 2005 (Date of Inception) to September 30, 2008

Series A preferred stock

9,999,999

 

-

 

5,887,919

Series B preferred stock

6,320,498

 

5,880,104

 

3,845,509

Series B warrants

732,501

 

718,908

 

425,263

Common stock options and warrants

2,627,174

 

5,575,750

 

2,346,353

Unvested restricted stock

1,100,000

 

250,000

 

1,574,193

Total weighted average number of potentially dilutive shares excluded from the diluted net loss per share calculation

20,780,172

 

12,424,762

 

14,079,237


Series A preferred stock was converted to common stock on a 1:1 basis effective December 7, 2007.

Comprehensive Income. Statement of Financial Accounting Standards No. 130, " Reporting Comprehensive Income" ("SFAS 130"), requires that an enterprise report, by major components and as a single total, the change in its net assets from non-owner sources. The Company’s other comprehensive income consists solely of cumulative currency translation adjustments resulting from the translation of the financial statements of its foreign subsidiaries. The tax effects on the foreign currency translation adjustments have not been significant.

Foreign Currency Translation/Transactions.   Assets and liabilities of non-U.S. subsidiaries that operate in a local currency environment, where that local currency is the functional currency, are translated into U.S. dollars at exchange rates in effect at the balance sheet date; with the resulting translation adjustments directly recorded to a separate component of accumulated other comprehensive income. Income and expense accounts are translated at average exchange rates during the year. Gains and losses from foreign currency transactions are recorded in other income (loss), net. The functional currency is the local currency for all non-U.S. subsidiaries.

Restricted Stock. The Company has granted restricted stock awards, restricted by a service condition, with vesting periods of up to three years. Restricted stock awards are valued using the fair market value of the Company’s common stock as of the date of grant. The Company recognizes compensation expense on a straight line basis over the requisite service period of the award. The remaining unvested shares are subject to forfeitures, repurchase and restrictions on sale, or transfer, up until the vesting date.

Stock-Based Compensation Expense. Effective January 1, 2006, we adopted the fair value recognition provisions of SFAS No. 123 (Revised 2004), “ Share-Based Payment ” (“SFAS 123(R)”), requiring us to recognize expense related to the fair value of our stock-based compensation awards adjusted to reflect only those shares that are expected to vest. Our implementation of SFAS 123(R) used the modified-prospective-transition method.

We made the following estimates and assumptions in determining fair value:

·

Valuation and Amortization Method — We estimate the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period.

·

Expected Term — The expected term represents the weighted-average period that our stock-based awards are expected to be outstanding. We applied the “Simplified Method” as defined in the Securities and Exchange Commission’s Staff Accounting Bulletin No. 107 and 110.



8




AE BIOFUELS, INC.

(A Development Stage Company)


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)




1.

Nature of Activities and Summary of Significant Accounting Policies (contd.).

·

Expected Volatility — The expected volatility is calculated by considering, among other things, the expected volatilities of public companies engaged in similar industries.

·

Expected Dividend — The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company currently pays no dividends and does not expect to pay dividends in the foreseeable future.

·

Risk-Free Interest Rate — The Company bases the risk-free interest rate on the implied yield currently available on United States Treasury zero-coupon issues with an equivalent remaining term.

Recent Accounting Pronouncements

In September 2006, the FASB issued Statement No. 157, “ Fair Value Measurements ” (“SFAS 157”). SFAS 157 defines fair value, establishes a framework and gives guidance regarding the methods used in measuring fair value, and expands disclosures about fair value measurements.  SFAS 157 is applicable whenever another accounting pronouncement requires or permits assets and liabilities to be measured at fair value.  SFAS 157 does not expand or require any new fair value measures; however the application of this statement may change current practice.  On January 1, 2008, the Company adopted SFAS 157 and the adoption of this statement had no material effect on the Company’s financial statements.  On February 12, 2008, the FASB issued FASB Staff Position (FSP) No. 157-2, “Effective date of FASB Statement No. 157.”  FSP 157-2 delays the effective date of adoption for nonfinancial assets and liabilities to fiscal years beginning after November 15, 2008.  As such, the Company will adopt the provisions of SFAS 157 with respect to non-recurring fair value measurements for non-financial assets and liabilities as of January 1, 2009.

In February 2007, the FASB issued SFAS No. 159, “ The Fair Value Option for Financial Assets and Financial Liabilities-Including an Amendment of FASB Statement No. 115 ” ("SFAS 159").  This statement permits entities to choose to measure many financial instruments and certain other items at fair value.  The fair value option may be elected on an instrument-by-instrument basis, with few exceptions. SFAS 159 also establishes presentation and disclosure requirements to facilitate comparisons between companies that choose different measurement attributes for similar assets and liabilities.  On January 1, 2008, the Company adopted SFAS 159 and the adoption of this statement had no material effect on the Company’s financial statements.

In December 2007, the FASB issued SFAS No. 141(R), “ Business Combinations ” (“SFAS 141R”). This statement changes the accounting for acquisition transaction costs by requiring them to be expensed in the period incurred, and also changes the accounting for contingent consideration, acquired contingencies and restructuring costs related to an acquisition.  Also in December 2007, the FASB issued SFAS No. 160, “ Non-controlling Interests in Consolidated Financial Statements-an amendment of ARB No. 51 ” (“SFAS 160”).  This statement will change the accounting and reporting for minority interests, which will be re-characterized as non controlling interests, classified as a component of equity and accounted for at fair value. SFAS 141(R) and SFAS 160 are effective for the Company’s 2009 financial statements.  Early adoption is prohibited.  The effect the adoption of SFAS 141(R) and SFAS 160 will have on the Company’s financial statements will depend on the nature and size of acquisitions we complete after we adopt SFAS 141(R) and SFAS 160.

In May 2008, the FASB issued SFAS No. 162, “ The Hierarchy of Generally Accepted Accounting Principles” (“SFAS No. 162”).  The current GAAP hierarchy was established by the American Institute of Certified Public Accountants, and faced criticism because it was directed to auditors rather than entities.  The issuance of this statement corrects this and makes some other hierarchy changes.  This statement is effective 60 days following the Securities and Exchange Commission’s approval of the Public Company Accounting Oversight Board amendments to AU Section 411, “ The Meaning of Present Fairly in Conformity with Generally Accepted Accounting Principles”  The FASB does not expect that this statement will result in a change to current practice.

In May 2008, the FASB issued Staff Position No. APB 14-1, “ Accounting for Convertible Debt Instruments That May be Settled in Cash upon Conversion (Including Partial Cash Settlement)” (“FSP APB 14-1”).  FSP APB 14-1 states that convertible debt instruments that may be settled in cash upon conversion (including partial cash settlement) are not addressed by paragraph 12 of Accounting Principles Board Opinion No. 14 and that issuers of such instruments should account separately for the liability and equity components of the instruments in a manner that will reflect the entity’s nonconvertible debt borrowing rate when interest cost is recognized in subsequent periods. FSP APB 14-1 is effective for financial statements issued for fiscal years beginning after December 15, 2008, and must be applied retrospectively to all periods presented.  The Company is currently evaluating the impact that FSP APB 14-1 will have on its consolidated financial statements.



9




AE BIOFUELS, INC.

(A Development Stage Company)


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)




1.

Nature of Activities and Summary of Significant Accounting Policies (contd.).

In April 2008, the FASB issued FASB Staff Position Financial Accounting Standard 142-3 (“FSP FAS 142-3”), “Determination of the Useful Life of Intangible Assets.” FSP FAS 142-3 amends the factors that should be considered in developing renewal or extension assumptions used to determine the useful life of a recognized intangible asset under SFAS No. 142 ("SFAS 142"), “Goodwill and Other Intangible Assets.”  The intent of the FSP is to improve the consistency between the useful life of a recognized intangible asset under SFAS 142 and the period of expected cash flows used to measure the fair value of the asset under SFAS No. 141, "Business Combinations."  We are required to adopt FSP FAS 142-3 in the first quarter of 2009 and will apply it prospectively to intangible assets acquired after the effective date.  We do not currently believe that adopting FSP FAS 142-3 will have a material impact on our Consolidated Financial Statements.

In June 2008, the FASB ratified EITF Issue 07-5, “Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock” (“EITF 07-5”). Paragraph 11(a) of Statement of Financial Accounting Standard No 133 “ Accounting for Derivatives and Hedging Activities ” (“SFAS 133”) specifies that a contract that would otherwise meet the definition of a derivative but is both (a) indexed to the Company’s own stock and (b) classified in stockholders’ equity in the statement of financial position would not be considered a derivative financial instrument.  EITF 07-5 provides a new two-step model to be applied in determining whether a financial instrument or an embedded feature is indexed to an issuer’s own stock and thus able to qualify for the SFAS 133 paragraph 11(a) scope exception. EITF 07-5 will be effective for the first annual reporting period beginning after December 15, 2008, and early adoption is prohibited.  The Company is evaluating the impact that this standard will have on its consolidated financial statements.

2.

Ability to Continue as a Going Concern.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has experienced losses and negative cash flow since inception and currently has an accumulated deficit and negative working capital. These factors raise substantial doubt about its ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent on several factors.

The Company has had minimal revenues and has incurred losses from inception through September 30, 2008. The Company has raised approximately $31.8 million dollars to date through the sale of preferred stock (net of placement fees). An additional $8 million of cash was generated through the dissolution of the Sutton Ethanol joint venture.  The Company obtained an additional $11 million in debt from senior secured notes and a term loan. The Company will have to raise significantly more capital or secure a significant amount of debt to complete its business plan and continue as a going concern. Management completed the commissioning of the facility in India on October 1, 2008 and plans to begin operations of this biodiesel facility during the fourth quarter of 2008.

The Company will need significantly more cash to implement its plan to build next-generation ethanol plants, to continue to develop biodiesel facilities in India, to consummate the proposed acquisition of an ethanol plant and distribution business in Wyoming and to develop biodiesel facilities in South America. The Company intends to raise these funds through the sale of additional equity either in AE Biofuels or one of our subsidiaries, joint ventures, construction loans, long-term debt financings and operating cash flows. We estimate that the cost to develop a biodiesel facility in India or South America is approximately $30 million to $50 million with an additional $6 million to $10 million required for working capital.

The Company today is spending approximately $645,000 per month for its general and administrative and research and development costs. Funds available at September 30, 2008 are sufficient to cover less than one month of our domestic operating costs. During the nine months ended September 30, 2008, we borrowed $650,000 under the credit facility established with a former member of the Company’s board of directors and significant shareholder, in order to meet our funding obligations with respect to our Energy Enzymes subsidiary and meet current obligations. Subsequent to September 30, 2008, we borrowed an additional $ 500,000 under this credit facility.  Due to the risk factors discussed in our annual report on form 10-K and in this quarterly report on form 10-Q, there can be no assurance that we will be successful in raising the additional funds necessary to carry out management’s plans for the future. Management estimates that it will need to obtain additional debt or equity funds for each ethanol and biodiesel facility it builds, plus cash to continue its development efforts.



10




AE BIOFUELS, INC.

(A Development Stage Company)


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)




3.

Inventory.

Inventory consists of the following:


 

 

September 30,

2008

 

December 31,

2007

 

 

 

 

 

 

 

 

 

Raw Materials

 

$

65,208

 

$

-

 

Finished Goods

 

 

1,188,800

 

 

-

 

Total inventory

 

$

1,254,008

 

$

-

 


For the three months ended September 30, 2008, the Company expensed $952,028 in connection with the write-down of inventory to reflect market value below cost.

4.

Property, Plant and Equipment.

Property, plant and equipment consist of the following:


 

 

September 30,

2008

 

December 31,

2007

 

 

 

 

 

 

 

 

 

Land

 

$

3,682,547

 

$

3,734,623

 

Furniture and fixtures

 

 

52,747

 

 

52,747

 

Machinery and equipment

 

 

410,103

 

 

-

 

Construction in progress

 

 

17,802,126

 

 

15,800,752

 

Total gross property, plant and equipment

 

 

21,947,523

 

 

19,588,122

 

Less accumulated depreciation

 

 

(21,105

)

 

(3,035

)

Total net property, plant and equipment

 

$

21,926,418

 

$

19,585,087

 

Components of construction in progress include $15,748,177 related to our India biodiesel production facility (expected to be placed in service during the fourth quarter of 2008) and $2,053,949 related to the development of our Sutton property (held for future development of an ethanol facility).

5.

Other Assets.

Other assets consist of the following:


 

 

September 30,

2008

 

December 31,

2007

 

Current

 

 

 

 

 

 

 

Letter of credit securing material purchases

 

$

-

 

$

500,000

 

Short term deposits

 

 

234,419

 

 

-

 

Land options

 

 

40,000

 

 

164,536

 

Other

 

 

59,743

 

 

9,699

 

 

 

$

334,162

 

$

674,235

 

Long Term

 

 

 

 

 

 

 

Domain names

 

 

46,098

 

 

46,098

 

Deposits

 

 

437,131

 

 

22,390

 

 

 

$

483,229

 

$

68,488

 




11




AE BIOFUELS, INC.

(A Development Stage Company)


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)




6.

Intangible Assets.

Intangible assets consist of purchased customer lists (acquired in 2007 in connection with the Biofuels Marketing acquisition discussed in Note 12) which are being amortized over an estimated useful life of 18 months. Intangible assets had a net carrying amount of $83,334 and $233,334 as of September 30, 2008 and December 31, 2007, respectively.

7.

Debt.

Debt consists of the following:

 

 

September 30,

2008

 

December 31,

2007

 

 

 

 

 

 

 

 

 

Secured term loan, net of discount

 

 

4,171,922

 

 

-

 

Revolving line of credit (related party)

 

 

1,300,495

 

 

-

 

Less: current portion

 

 

(538,213

)

 

-

 

Long term debt

 

 

4,934,204

 

 

-

 

Senior secured note, net of discounts

 

 

4,173,437

 

 

 

 

Current portion of long term debt

 

 

538,213

 

 

-

 

Total debt

 

$

9,645,854

 

$

-

 

On May 16, 2008, Third Eye Capital ABL Opportunities Fund (“Purchaser”) purchased a 10% senior secured note in the amount of $5 million along with warrants exercisable for 250,000 shares of common stock at an exercise price of $3.00 per share. The Note is secured by first-lien deeds of trust on real property located in Nebraska and Illinois, by a first priority security interest in equipment located in Montana, and a guarantee of $1 million by McAfee Capital LLC (owned by Eric McAfee and his wife). Interest on the Note accrues on the unpaid principal balance and is payable on the first business day of each quarter beginning on July 1, 2008. We may prepay all or any portion of the outstanding principal amount of the Note at any time. The Note matures on May 15, 2009, and at that time the outstanding principal amount of the Note together with all accrued and unpaid interest thereon will become due. At September 30, 2008 the Company was not in compliance with the current ratio covenant for the month of September under the loan agreement and is working with the lender to obtain a waiver of this covenant.    While we expect to obtain a waiver, in the event we are unable to do so, the interest rate under this facility increases by 8% and, at the option of the lender, the indebtedness may become immediately due and payable.  The Company has no cross default provisions in this or any other debt agreement. As a result, our inability to obtain a waiver will have no adverse impact on our other debt obligations.  Nevertheless, the failure to obtain a waiver or the acceleration of this debt obligation as a result of this breach may have an adverse impact on our ability to obtain additional borrowings.   There is no assurance that the Company will be able to obtain alternative funding in the event this debt obligation is accelerated.  Immediate acceleration would have a significant adverse impact on the Company’s near term liquidity.

A discount to the Note was recorded based on the relative fair value of the 250,000 warrants issued with the Note. For purposes of the relative fair value allocation, the warrants were valued using a Black-Scholes valuation with the following assumptions: five year term, volatility of 58.7%, no dividends and a risk free interest rate of 3.66%. The fair value of the Note was estimated using a discounted cash flow analysis. The resulting discount of $822,500, combined with a discount of $500,000 related to cash issuance costs, will be amortized over one year, the term of the Note.  Amortization of this discount for the three and nine months ended September 30, 2008 was $330,625 and $495,937, respectively.

On July 17, 2008, Universal Biofuels Private Limited (“UBPL”), a wholly-owned subsidiary entered into a five year secured term loan with the State Bank of India in the amount of approximately $6 million. The term loan matures in July 2013 and is secured by UBPL’s assets, consisting of the biodiesel plant and land in Kakinada, India.  Repayments begin June 2009 with quarterly payments in the amount of approximately $275,000.  In addition, Suren Ajjarapu, a former officer and member of the Company’s board of directors, entered into a Deed of Overall Guarantee on October 16, 2008. Borrowings under this facility generally bear interest at 12.75% and the rate is subject to adjustment after two years.

D uring the nine month period ended September 30, 2008, Laird Cagan, a former member of the Company’s board of directors, provided project financing to the Energy Enzymes subsidiary.  At September 30, 2008, a total of $1,300,000 was outstanding under this credit facility which accrues interest at 10% interest per annum.  All outstanding principal and accrued interest is due and payable on January 31, 2011.  On September 5, 2008 this credit facility was amended which converted the facility into a revolving line of credit with a credit limit of $2,000,000.  In addition, the maturity date of the credit facility was extended to January 31, 2011, and as a result was re-classified as long-term debt on the balance sheet.



12




AE BIOFUELS, INC.

(A Development Stage Company)


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)




8.

  Operating Leases.

The Company, through its subsidiaries, has non-cancelable operating leases for office space in various worldwide locations and the property housing our cellulosic demonstration facility in Butte, Montana. These leases expire at various dates through April 26, 2010. The operating lease for the Butte, Montana facility grants the Company the right to purchase the underlying land and building at the end of each lease year.  The Company records rent expense on a straight line basis.

Future minimum operating lease payments as of September 30, 2008 are:


  

 

Rental

Payments

 

 

 

 

 

2008 (remainder of 2008)

 

 

63,855

 

2009

 

 

201,575

 

2010

 

 

4,348

 

 

 

$

269,778

 


9.

Stockholders Equity.

The Company is authorized to issue up to 400,000,000 shares of common stock, $0.001 par value per share and 65,000,000 shares of preferred stock, $0.001 par value per share.

Convertible Preferred Stock

Our Articles of Incorporation authorize our board to issue up to 65,000,000 shares of preferred stock, $0.001 par value per share, in one or more classes or series within a class upon authority of the board without further stockholder approval, of which 7,235,402 shares were designated Series B preferred stock. There were 5,533,821 and 6,487,491 shares of Series B preferred stock issued and outstanding as of September 30, 2008 and December 31, 2007, respectively.

Significant terms of the Series B preferred stock are as follows:

Voting. Holders of our Series B preferred stock are entitled to the number of votes equal to the number of shares of Common Stock into which the shares of preferred stock held by such holder could be converted as of the record date. Cumulative voting with respect to the election of directors is not allowed. Currently, each share of Series B preferred stock is entitled to one vote per share. In addition, without obtaining the approval of the holders of a majority of the outstanding preferred stock, the Company cannot:

·

Increase or decrease (other than by redemption or conversion) the total number of authorized shares of Series B preferred stock;

·

Effect an exchange, reclassification, or cancellation of all or a part of the Series B preferred stock, including a reverse stock split, but excluding a stock split;

·

Effect an exchange, or create a right of exchange, of all or part of the shares of another class of shares into shares of Series B preferred stock; or

·

Alter or change the rights, preferences or privileges of the shares of Series B preferred stock so as to affect adversely the shares of such series.

Dividends . Holders of shares of Series B preferred stock are entitled to receive non-cumulative dividends payable in preference and prior to any declaration or payment of any dividend on common stock as may from time to time be declared by the board of directors out of funds legally available for that purpose at the rate of 5% of the original purchase price of such shares of preferred stock. No dividends may be made with respect to our common stock until all declared dividends on the preferred stock have been paid or set aside for payment to the preferred stock holders. To date, no dividends have been declared.



13




AE BIOFUELS, INC.

(A Development Stage Company)


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)




9.

Stockholders Equity (contd.).

Liquidation Preference. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of the Series B preferred stock are entitled to receive, prior and in preference to any payment to the holders of the common stock, $3.00 per share plus all declared but unpaid dividends (if any) on the Series B preferred stock. If the Company’s assets legally available for distribution to the holders of the Series B preferred stock are insufficient to permit the payment to such holders of their full liquidation preference, then the Company’s entire assets legally available for distribution are distributed to the holders of the Series B preferred stock in proportion to their liquidation preferences. After the payment to the holders of the Series B preferred stock of their liquidation preference, the Company’s remaining assets legally available for distribution are distributed to the holders of the common stock in proportion to the number of shares of common stock held by them. A liquidation, dissolution or winding up includes (a) the acquisition of the Company by another entity by means of any transaction or series of related transactions to which the Company is a party (including, without limitation, any stock acquisition, reorganization, merger or consolidation but excluding any sale of stock for capital raising purposes) that results in the voting securities of the Company outstanding immediately prior thereto failing to represent immediately after such transaction or series of transactions (either by remaining outstanding or by being converted into voting securities of the surviving entity or the entity that controls such surviving entity) a majority of the total voting power represented by the outstanding voting securities of the Company, such surviving entity or the entity that controls such surviving entity, or (b) a sale, lease or other conveyance of all or substantially all of the assets of the Company.

Conversion. Holders of Series B preferred stock have the right, at their option at any time, to convert their shares of Series B preferred stock into common stock at the then effective conversion rate, initially and currently at a one for one rate. The conversion rate is subject to adjustment from time to time in the event of certain dilutive issuances and events, such as stock splits, stock dividends, stock combinations, reclassifications, exchanges and the like. In addition, at such time as a registration statement covering the resale of the shares of common stock issuable upon conversion of the Series B preferred stock has been declared effective by the Securities and Exchange Commission ("SEC"), all outstanding Series B preferred stock shall be automatically converted into common stock at the then effective conversion rate.

Registration Rights Obligation.   Certain holders of shares of our common stock (including holders of warrants exercisable for common stock) and holders of shares of our Series B preferred stock (including holders of warrants exercisable for Series B preferred stock) are entitled to have their shares of common stock (including common stock issuable upon conversion of Series B preferred stock and exercise of warrants) registered under the Securities Act. Registration of these shares under the Securities Act would result in these shares becoming freely tradable without restriction under the Securities Act.

The registration rights granted by the Company require the Company to pay to the holders of these rights an amount equal to 0.5% of the aggregate dollar amount of securities purchased by such investors for each month or portion thereof after January 6, 2007 if the Company fails to file a registration statement with the SEC. The payments are treated as liquidated damages and not as a penalty and are full compensation to the investors, and shall constitute the investor's exclusive remedy for such events. At the Company’s option, the amounts payable as liquidated damages may be paid in cash or in shares of the Company's common stock.

The securities with registration rights described above may be sold under Rule 144, beginning December 15, 2008, at which time the payment obligation shall cease. The Company has elected to pay the Registration Rights Payment in shares of its common stock. The Company expects to issue shares of its common stock for the 12 month period ending December 12, 2008 with an aggregate value of $2,274,402, which were expensed as a Registration Rights Obligation and reflected as a component of Other Income/Expense in the Statement of Operations.

10.

Private Placement of Preferred Stock and Warrants.

In connection with the sale of our Series A and B preferred stock, we issued to our placement agent warrants to purchase a number of shares of our common, Series A, and Series B stock representing up to 8% of the shares of Series A and Series B preferred stock sold. The warrants are exercisable for a period of seven years from the date of issuance, have a net exercise provision and are transferable. The shares of the Company’s common stock issuable upon exercise of the warrants must be included in any registration statement filed by the Company with the SEC. Further, subject to certain conditions, the Company has indemnified the placement agents and affiliated broker-dealers against certain civil liabilities, including liabilities under the Securities Act.



14




AE BIOFUELS, INC.

(A Development Stage Company)


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)




10.

Private Placement of Preferred Stock and Warrants. (contd.)

A summary of warrant activity for placement agent warrants for 2008 is as follows:

 

 

 

Number of

Warrants

 

Weighted-

Average

Exercise

Price

 

Warrants

Exercisable

 

Remaining

Term

(years)

 

Outstanding, December 31, 2007

 

 

1,548,074

 

$

2.22

 

 

1,548,074

 

 

6.1

 

Exercised

 

 

(29,166

)

 

3.00

 

 

(29,166

)

 

 

 

Outstanding, September 30, 2008

 

 

1,518,908  

 

 

2.21

 

 

1,518,908

 

 

5.35

 


The warrants are considered equity instruments. Since they were issued as a cost of the issuance of the Series A and B preferred stock, the fair value of these warrants has effectively been netted against the preferred stock sale proceeds.

A former member of the Company’s board of directors and a significant shareholder of the Company is a registered representative of the placement agent. He received 976,721 warrants pursuant to the Series A and B financings (see Note 15).

Warrants

In February 2007, we issued five year warrants exercisable for 5,000 shares at $3.00 per share of the Company’s common stock to a consultant as compensation for services rendered. These warrants are immediately exercisable.

Common Stock Reserved for Issuance

AE Biofuels authorized the issuance of 4,000,000 shares under its 2007 Stock Plan for stock awards, which includes both incentive and non-statutory stock options. These options generally expire five years from the date of grant and are exercisable at any time after the date of the grant, subject to vesting. Shares issued upon exercise prior to vesting are subject to a right of repurchase, which lapses according to the vesting schedule of the original option.

The following is a summary of options granted under the 2007 Stock Plan:

 

 

 

Shares

Available

For Grant

 

Options Outstanding

 

 

 

 

Number

Of Shares

 

Weighted-Average

Exercise Price

 

 

 

 

 

 

Balance as of December 31, 2007

 

 

2,016,000

 

 

1,984,000

 

$

3.00

 

Authorized

 

 

-

 

 

 

 

 

 

 

Granted

 

 

(1,122,000

)

 

1,122,000

 

 

3.75

 

Exercised

 

 

-

 

 

-

 

 

-

 

Cancelled

 

 

20,250

 

 

(20,250

)

 

3.00

 

Balance as of September 30, 2008

 

 

914,250

 

 

3,085,750

 

$

3.27

 


At September 30, 2008, the weighted average remaining contractual term is 4.64 years. The aggregate intrinsic value of the shares outstanding at September 30, 2008 is $6,872,875. The aggregate intrinsic value represents the total pretax intrinsic value, based on the excess of the Company’s closing stock price of $5.50 as of September 30, 2008 over the option holders’ strike price, which would have been received by the option holders had all option holders exercised their options as of that date. The weighted average grant date fair value of these awards is $3.27.



15




AE BIOFUELS, INC.

(A Development Stage Company)


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)




10.

Private Placement of Preferred Stock and Warrants (contd.).

Included in the table above are 449,000 options issued to consultants in November 2007 and September 2008. These options had an exercise price of $3.00 and $3.70 and generally vest over three years. At September 30, 2008 the weighted average remaining contractual term was 4.22 years. The Company recorded a (credit)/charge to expense of ($80,839) and $410,772 for the three and nine months ended September 30, 2008, respectively, and $8,541 for the three and nine months ended September 30, 2007 which reflects the fair value valuation and periodic fair value remeasurement of outstanding consultant options under Emerging Issues Task Force, or EITF, No. 96-18, “Accounting for Equity Instruments That are Issued to Other Employees for Acquiring, or in Conjunction with Selling, Goods or Services,” (“EITF 96-18”). The valuation using the Black-Scholes model is based upon the current market value of our common stock and other current assumptions, including the expected term (contractual term for consultant options). The Company records the expense related to consultant options using the accelerated expense pattern prescribed in EITF 96-18.

Options vested and exercisable at September 30, 2008 and December 31, 2007 were 1,267,167 and 817,000, with weighted average exercise prices of $2.56 and $3.06, respectively.

Non-Plan Stock Options

In 2006, the Company issued 290,000 stock options to employees outside of any stock option plan, all of which were forfeited during the nine month period ended September 30, 2008.

11.

Stock Based Compensation.

The Company incurred non-cash, stock compensation charges of $216,739 and $1,777,722 in the three and nine months ended September 30, 2008, respectively and $855,995 and $924,945 in the three and nine months ended September 30, 2007, respectively in connection with options granted to employees and consultants.  Of the non-cash stock compensation charges for the nine months ended September 30, 2008, $800,000 was incurred as a result of the accelerated vesting of restricted stock in connection with the termination of one of our officers, which is treated for accounting purposes as a new award and revalued at the market value of the stock on the day of termination.

Valuation and Expense Information under SFAS 123(R)  

As of  September 30, 2008 and December 31, 2007, there was $3,057,623 and $2,585,196, respectively, of total unrecognized compensation expense under SFAS 123R, net of estimated forfeitures, related to stock options that the Company will amortize over the next four fiscal years.

12.

Acquisitions, Divestitures and Joint Ventures.

E85 Joint Venture . On January 17, 2007, American Ethanol, Inc. received a $5 million advance from E85, Inc., a Delaware corporation pursuant to a signed Memorandum of Understanding between the parties. E85, Inc. is an entity primarily owned by Mr. C. Sivasankaran, the founder and Chairman of Siva Limited, Sterling Infotech, and other businesses.

Subsequently, on March 1, 2007, American Ethanol entered into various agreements, including a Joint Development Agreement, with E85, Inc. The transactions caused no dilution to American Ethanol shareholders, and no shares or warrants were issued. Terms of the agreement included binding terms related to funding the expected $200 million construction of American Ethanol’s Sutton, Nebraska ethanol plant, as well as non-binding terms related to funding three additional ethanol plants.

On August 14, 2007, by mutual agreement of the parties, American Ethanol and E85 dissolved their joint venture. American Ethanol purchased E85’s 50% interest in the Sutton Joint Venture for $16 million in cash which they borrowed on a short term basis from the Joint Venture. As part of this repurchase, American Ethanol terminated its design contract with Delta T and wrote off approximately $5.2 million in design work previously performed by Delta T and its contractors. This $5.2 million is included as an expense of the Company as of December 31, 2007. American Ethanol retained the remaining $8 million invested in the JV by E85. This $8 million gain has been included in the Statement of Operations as a gain from sale of subsidiary. All previous agreements between American Ethanol and E85, including the loan facilities with Siva Limited, were terminated as of the date of the repurchase of the interest in Sutton.



16




AE BIOFUELS, INC.

(A Development Stage Company)


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)




12.

Acquisitions, Divestitures and Joint Ventures (contd.).

Public Company Acquisition . On June 23, 2006, American Ethanol acquired approximately 88.3% of the outstanding common stock of Marwich II, Ltd. from three principal shareholders for $675,000. The purchase price, net of current year expenses ($662,406), was accounted for as a reduction of additional paid-in capital as a step in a reverse merger transaction. In connection with this transaction, three members of American Ethanol's management were named as directors of Marwich. Also on June 23, 2006, American Ethanol entered into an Agreement and Plan of Merger (subsequently amended and restated on July 19, 2007) with Marwich pursuant to which effective December 7, 2007, American Ethanol merged with and into Marwich and (i) each issued and outstanding share of American Ethanol common stock (including common stock issued upon conversion of American Ethanol Series A preferred stock, which automatically converted into common stock immediately prior to the closing of the Merger) and Series B preferred stock was converted into common stock and Series B preferred stock, respectively, of Marwich, and (ii) each issued and outstanding option and warrant exercisable for common stock or Series B preferred stock of American Ethanol was assumed and converted into an option or warrant exercisable for common stock or Series B preferred stock of Marwich. Upon the effectiveness of the Merger, Marwich changed its name to AE Biofuels, Inc. The 3,343,200 shares of Marwich purchased by American Ethanol were retired upon the completion of the Merger.

On December 7, 2007, the Merger was completed and the former shareholders of American Ethanol were issued 84,114,998 shares of AE Biofuels, Inc. common stock in exchange for all of the outstanding shares of American Ethanol common stock, 6,487,491 shares of AE Biofuels, Inc. Series B preferred stock in exchange for all of the issued and outstanding shares of American Ethanol’s Series B preferred stock, and AE Biofuels, Inc. assumed options and warrants exercisable for 4,229,000 shares of common stock and 748,074 shares of Series B preferred stock, respectively. For accounting purposes, the Merger was treated as a reverse acquisition with American Ethanol as the acquirer and the Company as the acquired party.

Marketing Company Acquisition. On September 1, 2007, American Ethanol acquired Biofuels Marketing, Inc., a Nevada corporation, in exchange for 200,000 shares of American Ethanol common stock valued at $3.00 per share. Of the shares issued, 50% are contingent upon the continued employment of the President of Biofuels Marketing through August 31, 2009, and will be accounted for as compensation expense as earned. Of the purchase price, $300,000 was assigned to the primary asset acquired, which was a customer list, which is being amortized over 18 months.

The acquisitions of Wahoo Ethanol, LLC, Sutton Ethanol, LLC, Illinois Valley Ethanol, LLC, were treated as capital transactions.  We accounted for the acquisition of Biofuels Marketing, Inc. using purchase accounting.  Subsequent to the acquisition, the financial results of these entities were consolidated.

Technology Company Formation. On February 28, 2007, in consideration for the agreement to fund cellulosic ethanol development efforts, the Company acquired a 51% interest in Energy Enzymes, Inc. The Company has the right to acquire the remaining 49% for 1,000,000 shares of the Company's common stock upon the fulfillment of certain performance milestones. As of September 30, 2008, the Company had funded approximately $807,023 under this agreement.  The performance milestones had not been met as of September 30, 2008.

India Company Formation. On July 14, 2006, the Company, through a wholly owned subsidiary, International Biofuels, Inc. and its wholly-owned subsidiary, International Biodiesel, Ltd., LLC, a Mauritius company, entered into a joint venture with Acalmar Oils & Fats Limited, an Indian company. The purpose of the joint venture was to build a biodiesel production facility with a nameplate capacity of 50 million gallons per year with such fuel being exported from India to the U.S. for sale. Under the terms of the joint venture the Company agreed to contribute approximately $15.4 million and Acalmar agreed to contribute its edible palm oil facility in India to the joint venture entity through a leasing arrangement. On August 22, 2007, the Company and Acalmar mutually terminated this lease agreement.

On January 23, 2008, International Biofuels, Ltd agreed to terminate the joint venture with Acalmar Oils and Fats, Ltd. including termination of Acalmar’s right to own or receive any ownership interest in the joint venture. The total cancellation price payable by International Biofuels was $900,000 and is classified in our Statement of Operations as a shareholder agreement cancellation payment.  For the three months ended September 30, 2008, $300,000 was paid to Acalmar by the Company, reducing the remaining balance due to Acalmar to $600,000 at September 30, 2008.

Argentina Project Company . On June 9, 2008, AE Biofuels Americas, Inc., a subsidiary of AE Biofuels, Inc. entered into an agreement to develop a biodiesel plant with a nameplate capacity of 75 million gallons per year located in San Lorenzo, Argentina, subject to certain closing conditions, and signed a preliminary engineering agreement. To date, $204,347 has been funded and expensed under the preliminary engineering agreement.  On August 10, 2008 the Company and DS Development S.A. mutually agreed to cancel the agreement (see Note 18).



17




AE BIOFUELS, INC.

(A Development Stage Company)


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)




13.

Land Options and Purchases.

The Company and its subsidiary, American Ethanol, Inc., have an option to purchase land in Illinois. The option gives the Company the right to  acquire the land for $934,000.  This option expires in May 2009.

14.

Commitments.

The Company contracted with Desmet Ballestra India Pvt. Ltd. to build a glycerin refinery and pre-treatment plant at our existing biodiesel plant in Kakinada, India. At September 30, 2008 and December 31, 2007, commitments under construction contracts were outstanding for approximately $128,000 and $1,850,000, respectively. Commitments under purchase orders and other short term construction contracts were $321,998 at September 30, 2008.

15.

Related Party Transactions.

During the nine month period ended September 30, 2008, Laird Cagan, a former member of the Company’s board of directors, provided project financing to the Energy Enzymes subsidiary At September 30, 2008, a total of $1,300,000 was outstanding under this credit facility which accrues interest at 10% interest per annum.  All outstanding principal and accrued interest is due and payable on January 31, 2011.  On September 5, 2008 this credit facility was amended which converted the facility into a revolving line of credit with a credit limit of $2,000,000.  In addition, the maturity date of the credit facility was extended to January 31, 2011.

Chadbourn Securities acted as one of the Company’s placement agents with respect to the Company’s Series B preferred stock offering in 2007. Laird Cagan, a former member of the board of directors and a significant shareholder is an agent of Chadbourn and received payments from Chadbourn related to the sale of stock along with other non-related parties.

The Company and Eric A. McAfee, the Company's Chief Executive Officer and Chairman of the board of directors, are parties to an agreement pursuant to which the Company pays Mr. McAfee a monthly salary of $10,000 per month for services rendered to the Company as its President and CEO. For the three and nine months ended September 30, 2008 and 2007, the Company paid Mr. McAfee $30,000 and $90,000, respectively, pursuant to this agreement.

The Company and CM Consulting are parties to an agreement pursuant to which the Company reimbursed CM Consulting for a minimum of 20 hours per month of time on an aircraft owned by CM Consulting until February 2008. The Company paid an upfront fee of $360,000 starting February 2006 for 24 months of usage. The contract expired in February 2008. The Company expensed $15,000 and $135,000 of this rental fee for the nine months ended September 30, 2008 and 2007, respectively. Eric A. McAfee, a director, officer and significant shareholder of the Company owns 50% of CM Consulting.

The Company and Cagan McAfee Capital Partners are parties to an agreement pursuant to which Cagan McAfee Capital Partners provides administrative and advisory services for a monthly fee of $15,000 plus expense reimbursement to the Company.  For the nine months ended September 30, 2008 and 2007, the Company paid Cagan McAfee Capital Partners $245,174 and $123,856, respectively.  Eric A. McAfee, an officer and member of the Company’s board of director and Laird Cagan, a former of the Company’s board of directors, together own 100% of Cagan McAfee Capital Partners.

TIC - The Industrial Company (TIC) and Delta-T are companies involved in the design and construction of ethanol plants in the United States. In 2006 the Company paid TIC and Delta-T approximately $7.5 million for services related to the design and initial construction work on the Company’s Sutton ethanol plant facility.  In August 2007, the Company and TIC terminated their relationship, and the company wrote off approximately $5.2 million in design work and construction in progress.  On October 6, 2008, the Company and TIC cancelled their Strategic Alliance Agreement and TIC agreed to return 4,000,000 shares of the Company’s common stock for a total payment of $500,000 by the Company.  (See Note 18)

During October and December 2007, the Company sold $6,127,727 of crude palm oil to Acalmar Oils and Fats, Ltd. Amounts due from Acalmar Oils and Fats, Ltd. have been presented on the balance sheet as Accounts receivable - related party. These sales were made at prevailing market rates.



18




AE BIOFUELS, INC.

(A Development Stage Company)


NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)




16.

Income Tax.

The Company files a consolidated federal income tax return. This return includes all corporate companies 80% or more owned by the Company as well as the Company’s pro-rata share of taxable income from pass-through entities in which Company holds an ownership interest. State tax returns are filed on a consolidated, combined or separate basis depending on the applicable laws relating to the Company and its subsidiaries.

We do not provide for U.S. income taxes on the undistributed earnings of our foreign subsidiaries, as we consider these to be permanently reinvested in the operations of such subsidiaries. At December 31, 2007, these undistributed earnings totaled approximately $598,000. If some of these earnings were distributed, some countries may impose withholding taxes. In addition, as foreign taxes have previously been paid on these earnings, we would expect to be entitled to a U.S. foreign tax credit that would reduce the U.S. taxes owed on such distribution. As such, it is not practicable to determine the net amount of the related unrecognized U.S. deferred tax liability.

We adopted the provisions of FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109” (“FIN 48”), on January 1, 2007, and there was no impact to our financial statements. FIN 48 clarifies the accounting for uncertainty in income tax positions. FIN 48 provides that the tax affects from an uncertain tax position can be recognized in our financial statements only if the position is more-likely-than-not of being sustained on audit, based on the technical merits of the position. Tax positions that meet the recognition threshold are reported at the largest amount that is more-likely-than-not to be realized. This determination requires a high degree of judgment and estimation. We periodically analyze and adjust amounts recorded for our uncertain tax positions, as events occur to warrant adjustment, such as when the statutory period for assessing tax on a given tax return or period expires or if tax authorities provide administrative guidance or a decision is rendered in the courts. Most of our unrecognized tax benefits would affect our effective tax rate if recognized. Furthermore, we do not reasonably expect the total amounts of unrecognized tax benefits to significantly increase or decrease within the next 12 months.  Net operating losses at December 31, 2007 and 2006 were $470,464 and $214,885, respectively which expire in 2027.

As of September 30, 2008 and December 31, 2007, our unrecognized tax benefits were not significant.

17.

Contingent Liabilities.

On March 28, 2008, the Cordillera Fund, L.P. (“Cordillera”) filed a complaint in the Clark County District Court of the State of Nevada against American Ethanol, Inc. and the Company. The complaint seeks a judicial declaration that Cordillera has a right to payment from the Company for its American Ethanol shares at fair market value pursuant to Nevada’s Dissenters’ Rights Statute, a judicial declaration that Cordillera is not a holder of Series B preferred stock in the Company under the provisions of that statute; and a permanent injunction compelling the Company to apply the Dissenters’ Rights Statute to Cordillera’s shares and reimburse Cordillera for its attorneys fees and costs.

On April 29, 2008, we filed a Motion to Transfer Venue, seeking a transfer to the Second Judicial District Court of the State of Nevada, located in Washoe County, Nevada. The Motion was granted on or about June 2, 2008 and the case is now pending in Washoe County.  At this time no estimate of a range of loss can be made therefore we have neither accrued for this contingent liability, nor disclosed a range of loss relating to this contingent liability.

The Company intends to vigorously defend this disputed claim of entitlement under the Nevada Dissenters’ Rights Statute. The Company believes based upon their interpretation of the facts surrounding this matter and Nevada law that they have meritorious defenses against any claims by Cordillera for dissenters ’ rights. However, any ultimate outcome of this matter is highly uncertain and difficult to predict at this early stage.

18.

Subsequent Events.

In October 2008, the Company borrowed an additional $500,000 under the credit facility provided by Laird Cagan, a former director (See Notes 7 and 15).

On October 6, 2008, the Company and TIC cancelled their Strategic Alliance Agreement and TIC agreed to return 4,000,000 shares of the Company’s common stock for a total payment of $500,000 by the Company of which $234,419 was paid to TIC upon the parties’ entry into the agreement and $265,581 is payable on or before December 30, 2008.  Upon cancellation of the agreement, TIC returned 1,880,000 shares and will return the remaining 2,120,000 shares upon the receipt of the final payment. In the event the final payment is not received on or before December 30, 2008, interest shall begin to accrue at the annual rate of 18% until paid in full.



19





Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This Quarterly Report on Form 10-Q (“Report”), including the “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements regarding future events and the future results of the Company that are based on current expectations, estimates, forecasts, and projections about the industry in which the Company operates and the beliefs and assumptions of the management of the Company. Words such as “expects,” “anticipates,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words, and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in this Report under the section entitled “Risk Factors” in Item 1A of Part II and elsewhere, and in other reports the Company files with the Securities and Exchange Commission (“SEC”), specifically the most recent Annual Report on Form 10-K. The Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

The following discussion is based upon our unaudited Consolidated Financial Statements included elsewhere in this report, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingencies. Actual results may differ from these estimates under different assumptions or conditions.

Company Overview

We develop, acquire, construct and operate next-generation fuel grade ethanol and biodiesel production facilities in the U.S. and abroad.  We own and operate a biodiesel production facility in Kakinada, State of Andra Pradesh, India, with a nameplate capacity of 50 million gallons per year (“MGY”).  During the quarter, we continued the construction of our glycerin refinery and pre-treatment facility at our Kakinada plant which will enable us to refine crude palm oil into refined palm oil, and produce industrial and pharmaceutical-grade glycerin for sale to the Indian market.  Biodiesel is produced from refined palm oil which is more expensive than crude palm oil.  Refined glycerin is extensively used in personal care products, pharmaceuticals, food and beverages, tobacco, alkyd resins, and other technical applications and typically commands a significantly higher price than crude glycerin.  We expect that our production facilities in India will produce biodiesel and glycerin for both domestic and international markets.  Our current facility is licensed for international sales, and we are in the process of domesticating the plant to allow us to sell into domestic markets in India.  We continue to evaluate sites for additional production facilities in the United States, India and South America.

Finally, in the third quarter of 2008, we completed construction of our cellulosic ethanol demonstration facility in Butte, Montana and continued to fund the optimization of our cellulosic ethanol technology for large-scale commercial implementation. This facility was officially opened on August 11, 2008.

Company Organization

AE Biofuels, Inc., through its wholly-owned subsidiary American Ethanol, Inc., owns operating subsidiaries. Through our subsidiary International Biodiesel, Inc., we own International Biofuels, Ltd, a Mauritius corporation and its subsidiary Universal Biofuels Private Ltd, an India company. Universal Biofuels Private Ltd. holds as its primary asset a biodiesel plant with the nameplate capacity of 50 MGY in Kakinada, India. Two other subsidiaries of American Ethanol, Sutton Ethanol, LLC and Danville Ethanol, Inc, hold future plant development assets including approximately 375 acres of land. Biofuels Marketing, Inc., a Delaware corporation was acquired by us on September 1, 2007, as a marketing organization whose purpose is to acquire feedstock and sell the commodities related to our ethanol and biodiesel plants. Energy Enzymes, Inc. is held as a 51% owned joint venture for the development of next-generation cellulosic ethanol.  The Company has the right to acquire the remaining 49% of Energy Enzymes for one million shares of the Company’s common stock upon the completion of certain milestones. AE Biofuels Americas was formed to hold South and Central American assets.



20





Nine Months Ended September 30, 2008 Compared To Nine Months Ended September 30, 2007

Revenues  

We had no revenues in either the nine months ended September 30, 2008 or September 30, 2007.

Expenses

For the period from November 29, 2005 (inception) through September 30, 2008, the Company was considered a development stage enterprise under Statement of Financial Accounting Standards (“SFAS”) No. 7 “ Development Stage Enterprises” .  Since inception we have focused our efforts on developing our business including, constructing our Kakinada biodiesel production facility, constructing our cellulosic demonstration facility, securing funding arrangements, and evaluating other related opportunities. We will remain a development stage company until planned principal operations have commenced and significant revenues have been generated from those operations.

Research and Development Expenses

During 2007, we acquired 51% of Energy Enzymes, Inc. and have subsequently funded the operating expenses of Energy Enzymes and its team to optimize cellulosic ethanol technology for large-scale commercial implementation. For the nine months ended September 30, 2008, we funded operating expenses of $828,458, consisting of expenses to build a demonstration facility of $570,341, consulting services of $182,786, and miscellaneous expenses.  For the nine months ended September 30, 2007, we funded operating expenses of $186,583 principally for the services of the key scientists.

General and Administrative Expenses

Principal areas of spending for general and administrative expenses are in the areas of employee compensation and professional services. We summarize our spending into eight components as follows:


 

 

Nine Months

Ended

September 30, 2008

%

 

Nine Months

Ended

September 30, 2007

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Salaries, wages and compensation

 

 

39

%

 

24

%

Supplies and services

 

 

6

%

 

6

%

Repair and maintenance

 

 

-

 

 

-

 

Taxes, insurance, rent and utilities

 

 

5

%

 

1

%

Professional services

 

 

34

%

 

21

%

Depreciation and amortization

 

 

2

%

 

-

 

Travel and entertainment

 

 

4

%

 

5

%

Miscellaneous expense

 

 

10

%

 

43

%

Total

 

 

100

%

 

100

%


The number of employees grew as a result of hiring in India. Compensation expense grew from approximately $2,787,682 for the nine months ended September 30, 2007 to approximately $3,219,279 for the nine months ended September 30, 2008. The increase was principally driven by the non-cash, stock compensation of approximately $1,364,743 for the nine months ended September 30, 2008 compared to the stock compensation of $916,403 for the nine months ended September 30, 2007. The increase in stock compensation expense is due to the vesting acceleration of a restricted stock grant for a departing executive. On an inception-to-date basis, we spent $7,088,658 on employee compensation, including approximately $2,518,438 of stock compensation charges.

For the nine months ended September 30, 2008, we spent $2,803,757 in professional services including a non-cash stock compensation charge of $413,039, legal fees of $622,514, accounting fees of $369,148, professional fees of $311,006, financial advisory fees of $198,578 and independent board member fees of $212,000. For the nine months ended September 30, 2007, we spent $2,470,796 in professional services of which $8,541 was for non-cash stock based compensation, legal fees of $1,245,050, accounting fees of $224,197, financing fees of $200,000, and other advisor and consultant fees.  On an inception-to-date basis, we spent $8,525,263 on professional services, including $559,751 of non-cash stock compensation for stock and options issued to consultants.



21





Other Income (Expense)

Pursuant to the terms of its Amended and Restated Registration Rights Agreement, beginning in January 2008 the Company was obligated to file a registration statement to register shares of common stock issued or issuable upon conversion of the Company's Series A and B preferred stock or pay in cash or shares of stock to these investors an amount equal to 0.5% per month of their investment amount. The expense related to this payment from the period from January through December 2008 of $2,274,402 is reflected in our Statement of Operations as a registration rights payment.

On January 23, 2008, we agreed to terminate the joint venture with Acalmar Oils and Fats, Ltd. including termination of Acalmar’s right to own or receive any ownership interest in the joint venture. The total cancellation price of $900,000 is reflected in our Statement of Operations as a shareholder agreement cancellation payment.

Interest expense increased as a result of debt facilities acquired by both the Company and its India subsidiary. These debt facilities included warrant coverage and discount fees which are amortized as part of interest expense. For the nine months ended September 30, 2008, we incurred interest expense of $846,513 partially offset by interest earned on excess cash of $32,544.

During the nine months ended September 30, 2008, we purchased and resold glycerin resulting in profits of $78,276 which were recorded as net other income.

Three Months Ended September 30, 2008 Compared to Three Months Ended September 30, 2007

Revenues  

We had no revenues for the three months ended September 30, 2008 or September 30, 2007.

Cost of Goods Sold  

For the three months ended September 30, 2008, the Company expensed $952,028 in connection with the write-down of inventory.

Expenses

Research and Development Expenses

For the three months ended September 30, 2008, we funded the operating expenses of Energy Enzymes, Inc. in the amount of $316,402 consisting of consulting services of $62,596 and the balance associated with costs of building of a commercial demonstration plant.

General and Administrative Expenses

Principal areas of spending for general and administrative expenses are in the areas of employee compensation and professional services. We summarize our spending into eight components as follows:


 

 

Three Months

Ended

September 30, 2008

%

 

Three Months

Ended

September 30, 2007

%

 

 

 

 

 

 

 

 

 

Salaries, wages and compensation

 

 

36

%

 

16

%

Supplies and services

 

 

4

%

 

5

%

Repair and maintenance

 

 

-

 

 

-

 

Taxes, insurance, rent and utilities

 

 

5

%

 

-

 

Professional services

 

 

27

%

 

16

%

Depreciation and amortization

 

 

2

%

 

1

%

Travel and entertainment

 

 

4

%

 

2

%

Miscellaneous expense

 

 

22

%

 

60

%

Total

 

 

100

%

 

100

%

 



22





Compensation expense for the three months ended September 30, 2008 was $870,978, a decrease of 509,476 from $1,380,454 for the three months ended September 30, 2007. The decrease was principally driven by non-cash, stock compensation of $297,578 for the three months ended September 30, 2008, compared to non-cash stock compensation of $855,995 for the three months ended September 30, 2007 driven by the issuance of stock options to executives with immediate vesting provisions.

Professional services decreased to $680,885 for the three months ended September 30, 2008 from $1,340,083 for the three months ended September 30, 2007. Professional services included non-cash stock compensation credit of $80,839 for stock and option grants to key consultants and advisors during the three months ended September 31, 2008 and none for the three months ended September 30, 2007.  Changes in stock compensation were driven by the change in our stock price and its impact on the stock compensation charges calculated under EITF 96-18.  In addition, we purchased lower levels of financial and marketing advisory services during the three months ended September 30, 2008.

For the three months ended September 30, 2007, the Company took a one time charge of $5,114,236 to reflect impairment of construction in progress for design work previously performed by Delta T and its subcontractors.

Other Income (Expense)

For the three months ended September 30, 2008 the Company incurred interest expense of $593,494 for interest, bond discount and warrant coverage costs.

Liquidity

The Company today is spending approximately $645,000 per month primarily on general and administrative and research and development costs. Funds available at September 30, 2008 are sufficient to cover less than one month of our domestic operating costs. Subsequent to the filing of this report, we incurred short term borrowings to meet operating costs. The Company will require significant cash to fund its operating expenses and working capital requirements primarily for general and administrative expenses, and the purchase of feedstock and other raw materials to operate its existing and future production facilities.


We intend to fund ongoing operations through operating cash flows, working capital lines of credit, construction loans, long-term debt, the sale of additional equity by the Company or its subsidiaries and joint ventures.  However, the impact on financial institutions from the current global credit and liquidity crisis may adversely affect the availability and cost of credit to the Company. There can be no assurance that governmental responses to the disruptions in the financial markets will stabilize the markets or increase liquidity and the availability of credit. We cannot assure you that we will be able to secure such financing on terms acceptable to us or the, or at all, any of which could harm our business.


Historical Sources and Uses of Cash

Operating Activities

Through September 30, 2008, net cash used in operating activities was $19,866,013 primarily to develop our business, including general and administrative and research and development costs. Net cash used in operating activities increased from $5,876,817 in the nine months ended September 30, 2007 to $7,299,880 in the nine months ended September 30, 2008 primarily as a result of an increase in inventory of $2,116,080 purchased in connection with the commissioning of our biodiesel plant in India.

Investing Activities

Through September 30, 2008, net cash used in investing activities was $21,797,562, which consisted primarily of $32,760,042 in purchases of property, plant and equipment relating to the construction of our biodiesel facility in India, our demonstration facility in Butte, MT and the purchase of potential plant sites in Nebraska and Illinois, offset by $2,775,000 provided by overpayment refunds, $8,206,000 provided as a result of the dissolution of our joint venture with E85 in August 2007 and $2,000,000 provided by the sale of our ethanol plant site in Wahoo, Nebraska.  

Financing Activities

Through September 30, 2008, we have raised $42,153,755 from financing activities, including $31,911,422 from the sale of equity (net of expense) and $10,382,333 in debt, of which $4,719,547 is proceeds from long-term debt and $5,662,786 is proceeds from short-term debt. At September 30, 2008, the Company’s long-term debt included $1,300,495 outstanding under a credit facility provided by a former director and



23





significant shareholder.  On September 5, 2008 this credit facility was amended which converted the facility into a revolving line of credit with a credit limit of $2,000,000.  In addition, the maturity date of the credit facility was extended to January 31, 2011.  As a result, during the quarter we reclassified this facility from short-term to long-term debt.  On July 17, 2008, the Company entered into a secured term loan in the amount of approximately $6,000,000 of which $4,171,922 was outstanding at September 30, 2008. At September 30, 2008 the Company was not in compliance with the current ratio covenant for the month of September under the Third Eye Capital ABL Opportunities Fund loan agreement and is working with the lender to obtain a waiver of this covenant.    While we expect to obtain a waiver, in the event we are unable to do so, the interest rate under this facility increases by 8% and, at the option of the lender, the indebtedness may become immediately due and payable.  The Company has no cross default provisions in this or any other debt agreement. As a result, our inability to obtain a waiver will have no adverse impact on our other debt obligations.  Nevertheless, the failure to obtain a waiver or the acceleration of this debt obligation as a result of this breach may have an adverse impact on our ability to obtain additional borrowings.   There is no assurance that the Company will be able to obtain alternative funding in the event this debt obligation is accelerated.  Immediate acceleration would have a significant adverse impact on the Company’s near term liquidity.

Other Factors Affecting Liquidity and Capital Resources

We will need significantly more cash to implement our plan to build next-generation ethanol plants, to continue to develop biodiesel facilities in India and elsewhere in the world, to consummate planned acquisitions, and to fund ongoing operations. We estimate that the cost to develop a biodiesel facility in India or South America is approximately $30 million to $50 million with an additional $6 million to $10 million required for working capital.

The Company expects to spend an additional $1,000,000 to complete the pre-treatment facility and glycerin refinery at its Kakinada plant of which commitments for approximately $450,000 under purchase orders and other short term construction contracts which were outstanding at September 30, 2008.  

Critical Accounting Policies

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of net sales and expenses for each period. The following represents a summary of our critical accounting policies, defined as those policies that we believe are the most important to the portrayal of our financial condition and results of operations and that require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain.

Impairment of Intangible and Long-Lived Assets     

Our intangible asset was derived from the acquisition of Biofuels Marketing on September 1, 2007. In accordance with SFAS No. 141, “ Business Combinations ,” we allocated the purchase price to the tangible assets, liabilities and intangible asset acquired based upon their estimated fair values. The principal asset was an intangible asset consisting of a customer list. All of the capitalizable costs of this acquisition were allocated to this customer list as the value of the remaining tangible and intangible assets were negligible. This customer list is being amortized over 18 months, its estimated useful life.

Our long-lived assets are primarily associated with our plant in Kakinada, India. This production facility was constructed in conjunction with our former partner, Acalmar Oils and Fats, during 2007. The first phase of the plant is currently operational and we are evaluating various feedstock agreements in order to fully utilize the facility. We are constructing a glycerin refinery and pre-treatment plant at our Kakinada facility, which is expected to be fully operational by the fourth quarter of 2008. Costs for building the plant remained in construction-in-progress at September 30, 2008, and will be reclassified once the plant is fully operational and placed in service.

We evaluate impairment of long-lived assets in accordance with SFAS No. 144, “ Accounting for the Impairment or Disposal of Long-Lived Assets. ” We assess the impairment of long-lived assets, including property and equipment and purchased intangibles subject to amortization, when events or changes in circumstances indicate that these assets have been impaired and we accordingly write them down to their new fair value. Forecasts of future cash flows are critical judgments in this process and are based on our experience and knowledge of our operations and the industries in which we operate and are critical to our impairment assessments. These forecasts could be significantly affected by future changes in market conditions, the economic environment, and capital spending decisions of our customers and inflation. For the year ended December 31, 2007 we recognized an impairment of approximately $5,114,000 due to non-recoverable engineering costs associated with the development efforts at our Sutton site.



24





Stock-Based Compensation

Effective January 1, 2006, we adopted the fair value recognition provisions of SFAS No.123 (Revised 2004), “ Share-Based Payment ” (“SFAS 123(R)”), where the fair value of each option is adjusted to reflect only those shares that are expected to vest. Our implementation of SFAS 123(R) used the modified-prospective-transition method where the compensation cost related to each unvested option as of January 1, 2006 was recalculated and any necessary adjustment was reported in the first quarter of adoption.

We made the following estimates and assumptions in determining fair value:

·

Valuation and amortization method — We estimate the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period.

·

Expected Term — The expected term represents the weighted-average period that our stock-based awards are expected to be outstanding. We applied the “Simplified Method” as defined in the Securities and Exchange Commission’s Staff Accounting Bulletin No. 107.

·

Expected Volatility — The Company’s expected volatilities are based on historical volatility of comparable companies’ stock.

·

Expected Dividend — The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company currently pays no dividends and does not expect to pay dividends in the foreseeable future.

·

Risk-Free Interest Rate — The Company bases the risk-free interest rate on the implied yield currently available on United States Treasury zero-coupon issues with an equivalent remaining term.

Given the absence of an active market for our common stock as a private company prior to the Merger with American Ethanol, our board of directors, the members of which we believe have extensive business, finance or venture capital experience, were required to estimate the fair value of our common stock for purposes of determining exercise prices for the options it granted. Our board of directors determined the estimated fair value of our common stock, based in part on an analysis of relevant metrics, including the following:

·

the prices for our convertible preferred stock sold to outside investors in arm’s-length transactions;

·

the rights, preferences and privileges of that convertible preferred stock relative to those of our common stock;

·

our operating and financial performance;

·

the hiring of key personnel;

·

the introduction of new products;

·

our stage of development and revenue growth;

·

the fact that the option grants involved illiquid securities in a private company;

·

the risks inherent in the development and expansion of our operations; and

·

the likelihood of achieving a liquidity event, such as an initial public offering or a sale of the Company, for the shares of common stock underlying the options given prevailing market conditions.

Recently Issued Accounting Pronouncements

Recent Accounting Pronouncements

In September 2006, the FASB issued Statement No. 157, “ Fair Value Measurements ” (“SFAS 157”). SFAS 157 defines fair value, establishes a framework and gives guidance regarding the methods used in measuring fair value, and expands disclosures about fair value measurements. SFAS 157 is applicable whenever another accounting pronouncement requires or permits assets and liabilities to be measured at fair value. SFAS 157 does not expand or require any new fair value measurements however, the application of this statement may change current practice. On January 1, 2008, the Company adopted SFAS 157 and the adoption of this statement had no material effect on the Company’s financial statements. On February 12, 2008, the FASB issued FASB Staff Position (FSP) No. 157-2, “Effective Date of FASB Statement No. 157.” FSP 157-2 delays the effective date of adoption for nonfinancial assets and liabilities to fiscal years beginning after November 15, 2008.  As such, the Company will adopt the provisions of SFAS 157 with respect to non-recurring fair value measurements for non-financial assets and liabilities as of January 1, 2009.



25





In February 2007, the FASB issued SFAS No. 159, “ The Fair Value Option for Financial Assets and Financial Liabilities-Including an Amendment of FASB Statement No. 115 ” ("SFAS 159"). This statement permits entities to choose to measure many financial instruments and certain other items at fair value. The fair value option may be elected on an instrument-by-instrument basis, with few exceptions. SFAS 159 also establishes presentation and disclosure requirements to facilitate comparisons between companies that choose different measurement attributes for similar assets and liabilities. On January 1, 2008, the Company adopted SFAS 159 and the adoption of this statement had no material effect on the Company’s financial statements.

In December 2007, the FASB issued SFAS No. 141(R), “ Business Combination ” (“SFAS 141R”). This statement changes the accounting for acquisition transaction costs by requiring them to be expensed in the period incurred, and also changes the accounting for contingent consideration, acquired contingencies and restructuring costs related to an acquisition. Also in December 2007, the FASB issued SFAS No. 160, “ Noncontrolling Interests in Consolidated Financial Statements-an amendment of ARB No. 51 ” (“SFAS 160”). This statement will change the accounting and reporting for minority interests, which will be recharacterized as noncontrolling interests, classified as a component of equity and accounted for at fair value. SFAS 141(R) and SFAS 160 are effective for the Company’s 2009 financial statements. Early adoption is prohibited. The effect the adoption of SFAS 141(R) and SFAS 160 will have on the Company’s financial statements will depend on the nature and size of acquisitions we complete after we adopt SFAS 141(R) and SFAS 160.

In May 2008, the FASB issued SFAS No. 162, “ The Hierarchy of Generally Accepted Accounting Principles” (“SFAS No. 162”). The current GAAP hierarchy was established by the American Institute of Certified Public Accountants, and faced criticism because it was directed to auditors rather than entities. The issuance of this statement corrects this and makes some other hierarchy changes. This statement is effective 60 days following the Securities and Exchange Commission’s approval of the Public Company Accounting Oversight Board amendments to AU Section 411, “ The Meaning of Present Fairly in Conformity with Generally Accepted Accounting Principles.” The FASB does not expect that this statement will result in a change to current practice.

In May 2008, the FASB issued Staff Position No. APB 14-1, “ Accounting for Convertible Debt Instruments That May be Settled in Cash upon Conversion (Including Partial Cash Settlement)” (“FSP APB 14-1”). FSP APB 14-1 states that convertible debt instruments that may be settled in cash upon conversion (including partial cash settlement) are not addressed by paragraph 12 of Accounting Principles Board Opinion No. 14 and that issuers of such instruments should account separately for the liability and equity components of the instruments in a manner that will reflect the entity’s nonconvertible debt borrowing rate when interest cost is recognized in subsequent periods. FSP APB 14-1 is effective for financial statements issued for fiscal years beginning after December 15, 2008, and must be applied retrospectively to all periods presented. The Company is currently evaluating the impact that FSP APB 14-1 will have on its consolidated financial statements.

In April 2008, the FASB issued FASB Staff Position Financial Accounting Standard 142-3 (“FSP FAS 142-3”), “Determination of the Useful Life of Intangible Assets.” FSP FAS 142-3 amends the factors that should be considered in developing renewal or extension assumptions used to determine the useful life of a recognized intangible asset under SFAS No. 142 ("SFAS 142"), “Goodwill and Other Intangible Assets.” The intent of the FSP is to improve the consistency between the useful life of a recognized intangible asset under SFAS 142 and the period of expected cash flows used to measure the fair value of the asset under SFAS No. 141, "Business Combinations." We are required to adopt FSP FAS 142-3 in the first quarter of 2009 and will apply it prospectively to intangible assets acquired after the effective date. We do not currently believe that adopting FSP FAS 142-3 will have a material impact on our Consolidated Financial Statements.

In June 2008, the FASB ratified EITF Issue 07-5, “Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock” (“EITF 07-5”). Paragraph 11(a) of Statement of Financial Accounting Standard No 133 “ Accounting for Derivatives and Hedging Activities ” (“SFAS 133”) specifies that a contract that would otherwise meet the definition of a derivative but is both (a) indexed to the Company’s own stock and (b) classified in stockholders’ equity in the statement of financial position would not be considered a derivative financial instrument. EITF 07-5 provides a new two-step model to be applied in determining whether a financial instrument or an embedded feature is indexed to an issuer’s own stock and thus able to qualify for the SFAS 133 paragraph 11(a) scope exception. EITF 07-5 will be effective for the first annual reporting period beginning after December 15, 2008, and early adoption is prohibited. The Company is evaluating the impact this standard will have on its consolidated financial statements.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Interest Rate Sensitivity

We had cash, cash equivalents and marketable securities totaling $591,718 and $3,356,294 at September 30, 2008 and December 31, 2007, respectively. These amounts were invested primarily in money market funds and short term time deposits. The unrestricted cash and cash equivalents and marketable securities are held for working capital purposes. We do not enter into investments for trading or speculative purposes. We believe that we do not have any material exposure to changes in the fair value as a result of changes in interest rates. Declines in interest rates, however, will reduce future investment income.

At September 30, 2008 and June 30, 2008, we had $4,173,437 and $5,600,000 of fixed-rate, short-term and long-term debt outstanding, respectively.  During the three months ended September 30, 2008, we entered into two forward contracts for crude palm oil.  We took delivery of the crude palm oil under the first contract and elected not to take delivery under the second contract by selling our position. As of September 30, 2008 we owed approximately $356,000 with respect to the second contract.



26










27





Item 4T. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company's management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) that is designed to ensure that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms. Based upon their evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of September 30, 2008 our disclosure controls and procedures were not effective. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer's management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting, during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting, except those discussed below with respect to our remediation efforts.

Remediation Efforts to Address Material Weakness in Internal Control over Financial Reporting

Throughout the nine months ended September 30, 2008, we began the implementation of a remediation plan to address the material weaknesses identified during the audit of our fiscal year ended December 31, 2007. The control deficiencies that gave rise to the material weaknesses related to the fact that our accounting resources did not include enough people with the detailed knowledge, experience and training in the selection and application of certain accounting principles generally accepted in the United States of America (GAAP) to meet our financial reporting needs. These control deficiencies contributed to material weaknesses in internal control with respect to segregation of duties, controls over financial reporting at the India subsidiary, stockholders equity and share-based compensation, acquisitions as well as financial statement presentation and disclosures. We have hired two employees with the necessary accounting knowledge, experience and training to meet the needs of our organization. We will continue to implement process changes and hire employees or consultants to address the material weaknesses noted in the internal controls over financial reporting for fiscal 2007. Once placed in operation for a sufficient period of time, we will evaluate the overall effectiveness of these new process changes to determine if they are operating effectively.

Inherent Limitations of Internal Controls

Our management, including our CEO and CFO, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.



28





PART II — OTHER INFORMATION

Item 1. Legal Proceedings

On March 28, 2008, the Cordillera Fund, L.P. ("Cordillera") filed a complaint in the Clark County District Court of the State of Nevada against American Ethanol, Inc. and the Company. The complaint seeks a judicial declaration that Cordillera has a right to payment from the Company for its American Ethanol shares at fair market value pursuant to Nevada's Dissenters' Rights Statute, a judicial declaration that Cordillera is not a holder of Series B preferred stock in the Company under the provisions of the statute; and a permanent injunction compelling the Company to apply the Dissenters' Rights Statute to Cordillera's shares and reimburse Cordillera for attorneys fees and costs.

On April 29, 2008, we filed a Motion to Transfer Venue, seeking a transfer to the Second Judicial Court of the State of Nevada, located in Washoe County, Nevada. The Motion was granted on or about June 2, 2008 and the case is now pending in Washoe County.

The Company intends to vigorously defend this disputed claim of entitlement under the Nevada Dissenters' Rights Statute.

Item 1A.  Risk Factors

Our business is subject to certain risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our common stock. For a discussion of these risks, please refer to Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2007 filed with the SEC on April 1, 2008. In addition, please consider the following:

We will need to obtain a significant amount of additional debt and equity capital to complete the development and completion of our planned ethanol and biodiesel plants, which we may not be able to obtain on acceptable terms or at all.

As of September 30, 2008, we had $133,666 in cash on hand in our domestic entities and $458,052 held in offshore subsidiaries including marketable securities.  We will require a significant amount of capital to meet our existing and future cash needs.  For example, until our biodiesel production facility in India generates sufficient positive cash flow, we will require a significant amount of working capital to purchase feedstock, operate the plant and pay overhead, and additional funding will be needed to meet ongoing obligations with respect to the completion of construction of our glycerin refinery and pre-treatment facility.  In addition, we will need to borrow an estimated $31 million to fund the acquisition of Renova Energy, Inc. and Wyoming Ethanol, LLC and ongoing working capital requirements.  Finally, we require substantial funds to fund the Company’s general and administrative costs.  The impact on financial institutions from the current global credit and liquidity crisis may adversely affect the availability and cost of credit to the Company. There can be no assurance that governmental responses to the disruptions in the financial markets will stabilize the markets or increase liquidity and the availability of credit. We cannot assure you that we will be able to secure such financing on terms acceptable to us or the, or at all, any of which could harm our business.

Our results of operations, financial position and business will be highly dependent on commodity prices, which are subject to significant volatility and uncertainty, and the availability of supplies, so our respective results could fluctuate substantially.

With the commencement of production at our India biodiesel production facility expected in the fourth quarter of 2008, our results will be substantially dependent on commodity prices, especially prices for palm oil and other feedstock, and petroleum. The commodity markets are experiencing extreme volatility and disruption.  In recent weeks, the volatility and disruption in the commodity markets have reached unprecedented levels.  As a result of the volatility of the prices for these items, our results may fluctuate substantially and we may experience periods of declining prices for our products and increasing costs for our raw materials, which could result in operating losses. Although we may attempt to offset a portion of the effects of fluctuations in prices by entering into forward contracts to supply feedstock or other items or by engaging in transactions involving exchange-traded futures contracts, the amount and duration of these hedging and other risk mitigation activities may vary substantially over time and these activities also involve substantial risks.

There are risks inherent in international operations that could hinder our international growth strategy.

Our ability to achieve future success will depend in part on the successful operation of our facilities outside the U.S.  We currently own and operate a biodiesel production facility in India and we expect to generate significant revenues from our operations in India and elsewhere in the world. There are difficulties and risks inherent in doing business on an international level that could adversely affect our international operations, including, among other things, the following:

·

burdensome regulatory requirements and unexpected changes in these requirements;

·

tariffs and other trade barriers;

·

difficulties in staffing and managing international operations;



29






·

accounting (including managing internal control over financial reporting in our non-U.S. subsidiaries), tax and legal complexities arising from international operations;

·

longer accounts receivable payment cycles and collection difficulties;

·

political and economic instability;

·

fluctuations in currency exchange rates;

·

potential difficulties in transferring funds generated overseas to the U.S. in a tax efficient manner;

·

seasonal reductions in business activity during the summer months in Europe and other parts of the world; and

·

potentially adverse tax consequences.

Operations in foreign countries also present risks associated with currency exchange and convertibility, inflation and repatriation of earnings. In some countries, economic and monetary conditions and other factors could affect our ability to convert our cash distributions to U.S. dollars or other freely convertible currencies, or to move funds from our accounts in these countries. Furthermore, the central bank of any of these countries may have the authority to suspend, restrict or otherwise impose conditions on foreign exchange transactions or to approve distributions to foreign investors.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3.

Defaults upon Senior Securities

At September 30, 2008 the Company was not in compliance with the current ratio covenant for the month of September under the Third Eye Capital ABL Opportunities Fund loan agreement and is working with the lender to obtain a waiver of this covenant.    While we expect to obtain a waiver, in the event we are unable to do so, the interest rate under this facility increases by 8% and, at the option of the lender, the indebtedness may become immediately due and payable.  The Company has no cross default provisions in this or any other debt agreement. As a result, our inability to obtain a waiver will have no adverse impact on our other debt obligations.  Nevertheless, the failure to obtain a waiver or the acceleration of this debt obligation as a result of this breach may have an adverse impact on our ability to obtain additional borrowings.   There is no assurance that the Company will be able to obtain alternative funding in the event this debt obligation is accelerated.  Immediate acceleration would have a significant adverse impact on the Company’s near term liquidity.

Item 4.

Submission of Matters to a Vote of Security Holders

None

Item 5.

Other Information

None

Item 6.

Exhibits

3.1

Articles of Incorporation of Marwich II, Ltd. (renamed AE Biofuels, Inc.) filed with Nevada Secretary of State on October 24, 2006 to correct previous filing on December 13, 2007

 

 

3.1.1

Amendment to Articles of Incorporation of Marwich II, Ltd. filed with the Nevada Secretary of State on October 11, 2007

 

 

10.12

TIC Agreement

 

 

31.1

Certifications pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

31.2

Certifications pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes- Oxley Act of 2002.

 

 

32.1

Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

32.2

Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.





30





SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 11, 2008


 

AE Biofuels, Inc.

 

 

By:

/s/ Eric A. McAfee

 

Eric A. McAfee

 

Chief Executive Officer

(Principal Executive Officer)




31


EXHIBIT 3.1

 

 

[EXHIBIT31002.GIF]

Dean Heller
Secretary of State
206 North Carson Street
Carson City, Nevada 89701-4299
(775) 684-5708
Website: secretaryofstate.biz

Articles of Incorporation
(PURSUANT TO NRS 78)



 





Entity #
E0784312006-4

Document Number:
20060682853-90

Date Filed:
10/24/2006 3:15:48 PM

In the office of

[EXHIBIT31004.GIF]


Dean Heller
Secretary of State
ABOVE SPACE IS FOR OFFICE USE ONLY


 

 

 

 

 

1.

Name of
Corporation
:

 

Marwich II, Ltd.

2.

Resident Agent
Name and Street Address:

(must be a Nevada address where process may be served)

 

David A. Garcia

 

 

Name

 

 

 

 

 

 

5441 Kietzke Lane, Second Floor

Reno,

 

NEVADA

89511

 

 

Street Address

City

 

 

Zip Code

 

 

 

 

,

 

 

 

 

Optional Mailing Address

City

 

State

 

Zip Code

 

3.

Shares :
(number of shares corporation is authorized to issue)

 

Number of shares
with par value: 425,000,000           Par value:    $0.001

Number of shares
without par value:

4.

Names & Addresses, of Board of Directors/Trustees : (each Director/Trustee must be a natural person at least 18 years of age; attach additional pages if more than two Directors/Trustees)

 

1.

Timothy S. Morris

 

 

 

 

 

 

Name

 

 

 

 

 

 

203 N. LaSalle Street, Suite 2100

Chicago,

 

 

IL

 

60601

 

 

 

Address

City

 

 

State

 

Zip Code

 

 

 

 

 

 

 

 

2.

William J. Maender

 

 

 

 

 

 

 

Name

 

 

 

 

 

 

203 N. LaSalle Street, Suite 2100

Chicago,

 

 

IL

 

60601

 

Address

City

 

 

State

 

Zip Code

 

 

 

 

 

 

 

 

3.

 

 

 

 

 

 

 

 

Name

 

 

 

 

 

 

 

 

,

 

 

 

 

 

 

Address

City

 

 

State

 

Zip Code

5.

Purpose :

(optional; see instructions)

 

The purpose of this Corporation shall be:

To engage in any lawful activity.

 

 

6.

Names, Addresses
and Signature of Incorporator:
(attach additional page if more than one incorporator)

 

David A. Garcia

 

[EXHIBIT31006.GIF]

 

 

 

Name

 

Signature

 

 

 

5441 Kietzke Lane, Second Floor

Reno,

 

 

NV

 

89511

 

 

 

Street Address

City

 

 

State

Zip Code

 

 

 

 

 

 

 

 

7.

Certificate of Acceptance of Appointment of Resident Agent:

 

I hereby accept appointment as Resident Agent for the above named corporation.

 

 

 

[EXHIBIT31008.GIF]

 

 

10-24-06

 

 

 

Authorized Signature of R. A. or On Behalf of R. A. Company

 

 

Date

 


See next page for additional provisions.

 

This form must be accompanied by appropriate fees. See attached fee schedule.

 




ATTACHMENT TO
ARTICLES OF INCORPORATION
OF
MARWICH II, LTD.

ARTICLE 8. DIRECTORS . The members of the governing board shall be styled directors. The number of directors may be increased or reduced in the manner provided for in the Bylaws of the Corporation.

ARTICLE 9. CLASSIFICATION OF CAPITAL STOCK . The Corporation is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and “Preferred Stock.” The total number of shares which the Corporation is authorized to issue is Four Hundred Twenty-Five Million (425,000,000) shares, Four Hundred Million (400,000,000) shares of which shall be Common Stock, $.001 par value (the “ Common Stock ”) and Twenty-Five Million (25,000,000) shares of which shall be Preferred Stock, $.001 par value (the “ Preferred Stock ”). The undesignated Preferred Stock may be issued from time to time in one or more series. The Board of Directors is hereby authorized, subject to any restrictions set forth herein or in any Certificate of Designation of Preferred Stock, to fix or alter the rights, preferences, privileges and restrictions of any wholly unissued series of Preferred Stock, and the number of shares constituting any such series or the designation thereof and to increase or decrease the number of shares of any such series subsequent to the issuance of shares of that series, including as may be required pursuant to the provisions hereof or of any Certificate of Designation of Preferred Stock, but not below the number of shares of such series then outstanding. In case the number of shares of any series shall so be decreased, the shares constituting such decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of such series.

Article 10. Voting .

A.

Restricted Class Voting . Except as otherwise expressly provided herein or in a Certificate of Designation of Preferred Stock or as required by law, the holders of Preferred Stock and the holders of Common Stock shall vote together and not as separate classes.

B.

No Series Voting . Other than as provided herein or in a Certificate of Designation or as required by law, there shall be no series voting.

C.

Common Stock . Each holder of shares of Common Stock shall be entitled to one vote for each share thereof held.

D.

  Preferred Stock . Each holder of Preferred Stock shall be entitled to the number of votes equal to the number of shares of Common Stock into which the shares of Preferred Stock held by such holder could be converted as of the record date. The holders of shares of the Preferred Stock shall be entitled to vote on all matters on which the Common Stock shall be entitled to vote. Holders of Preferred Stock shall be entitled to notice of any shareholders’ meeting in accordance with these Articles of Incorporation and the Bylaws of the Corporation. Fractional votes shall not, however, be permitted and any fractional voting rights

577455

Articles of Incorporation – Page 2




resulting from the above formula (after aggregating all shares into which shares of Preferred Stock held by each holder could be converted), shall be disregarded.

E.

Adjustment in Authorized Common Stock . Subject to the provisions of any Certificate of Designation of Preferred Stock, the number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares of Common Stock then outstanding) with the approval or consent of the holders of a majority of the outstanding Common Stock and Preferred Stock of the Corporation voting together as a single class.

F.

Preemptive Rights . Holders of Preferred Stock and holders of Common Stock shall not be entitled to any preemptive, subscription or similar rights in respect to any securities of the Corporation, except as specifically set forth herein or in any other document agreed to by the Corporation.

ARTICLE 11. DISTRIBUTIONS . Subject to the terms of these Articles of Incorporation and any Certificate of Designation of Preferred Stock, and to the fullest extent permitted by the Nevada Revised Statutes, the Corporation shall be expressly permitted to redeem, repurchase, or make distributions, as that term is defined in Section 78.191 of the Nevada Revised Statutes, with respect to the shares of its capital stock in all circumstances other than where doing so would cause the Corporation to be unable to pay its debts as they become due in the usual course of business.

ARTICLE 12. I NDEMNIFlCATION . The Corporation shall indemnify its officers and directors and may indemnify any other person to the fullest extent permitted by law. Any amendment, repeal or modification of any provision of this Article 9 shall not adversely affect any right or protection of any agent of this Corporation existing at the time of such amendment, repeal or modification.

ARTICLE 13. LIABILITY OF DIRECTORS AND OFFICERS . To the maximum extent permitted under the Nevada Revised Statutes, no director or officer of the corporation shall be personally liable to the corporation or its stockholders for damages as a result of any act or failure to act in his capacity as a director or officer.

577455

Articles of Incorporation – Page 3




EXHIBIT 10.12

AGREEMENT AND
MUTUAL WAIVER AND RELEASE

This Agreement and Mutual Waiver and Release (“Agreement”) is entered into effective as of the 26 th day of September 2008 (the “Effective Date”) by and between AE Biofuels, Inc., a Nevada corporation (“AEB”) of the first part and TIC – The Industrial Company, a Delaware corporation (“TIC”) of the second part. TIC and AEB are referred to individually as a “Party” and collectively as the “Parties.”

Recitals

A.

Pursuant to the terms of a Unit Purchase Agreement dated January 18, 2006 (the “Purchase Agreement”), TIC acquired one million units in American Ethanol, LLC (the “Original Shares”). AEB is the successor in all respects to American Ethanol, LLC. As a result of various corporate actions and stock splits, the Original Shares have been converted into four million shares of the common stock of AEB (the “Shares”). The Shares are represented by AEB stock certificate number 227-9, dated December 18, 2007 (the “Certificate”). AEB has agreed to purchase the Shares from TIC and TIC has agreed to convey the Shares to AEB all as more particularly provided in this Agreement.

B.

TIC and American Ethanol, LLC (together with Delta-T Corporation) previously entered into a Strategic Alliance Agreement dated as of January 18, 2006 (the “Alliance Agreement”). AEB is the successor to American Ethanol, LLC with respect to all of its rights and obligations under the Alliance Agreement. The Parties wish to confirm that the Alliance Agreement and all obligations and liabilities under it have terminated.

C.

TIC and AEB previously entered into a Services Agreement dated as of March 1, 2006 (the “Original Agreement”) and as subsequently amended by a First Amendment executed on approximately November 1, 2006 (the “First Amendment”). (The Original Agreement as amended by the First Amendment is referred to as the “Services Agreement”). The Parties wish to confirm that the Services Agreement and all obligations and liabilities under it have terminated.

D.

TIC performed various services for the benefit of AEB under the Services Agreement and received compensation from AEB for such services. TIC and AEB have agreed to release each other from all liability and claims arising from the Services Agreement and any services provided pursuant to it. TIC currently holds $234,419.00 as a result of dealings with AEB pursuant to the terms of the Services Agreement (the “Remaining Funds”). The Remaining Funds will be applied to the purchase price of the Shares.

NOW, THEREFORE, in consideration of the mutual promises, covenants and conditions stated in this Agreement, the Parties agree as follows:

1.0

Sale And Purchase Of Shares.






1.1

Purchase. TIC agrees to sell to AEB and AEB agrees to purchase from TIC all of the Shares.

1.2

Purchase Price. The consideration for the conveyance of the Shares shall be the amount set forth in Section 1.3 (the “Purchase Price”), payable as provided below, as well as the other agreements of the Parties set out in this Agreement.

1.3

Conveyance of Shares.

A. Within five business days of the mutual execution and delivery of this Agreement, TIC shall execute and deliver to Sean R. O’Halloran (“O’Halloran”) as counsel for AEB (i) a fully executed stock assignment in the form of Exhibit A attached to this Agreement for 1,880,000 of the Shares (the “Initial Shares”), and (ii) the Certificate. O’Halloran shall within five business days of his receipt of such materials return to TIC a new certificate for the remaining balance of the Shares in the amount of 2,120,000 (the “Remaining Shares”) as properly issued by AEB (the “Second Certificate”). The Purchase Price for the Initial Shares shall be $0.125 per Share, or a total of $234,419.00, which shall be paid by TIC’s retention of the Remaining Funds.

B. AEB shall purchase the Remaining Shares represented by the Second Certificate on or before December 30, 2008. The Purchase Price for the Remaining Shares shall be an amount equal to $265,581.00. To complete such purchase, AEB shall give notice to TIC that it intends to complete the purchase of the Remaining Shares and within 24 hours of such notice, shall wire to TIC the Purchase Price for the Remaining Shares. Within five business days of its receipt of the wired Purchase Price funds for the Remaining Shares, TIC shall execute and deliver to O’Halloran (i) a fully executed stock assignment in the form of Exhibit A attached to this Agreement for the Remaining Shares, and (ii) the Second Certificate.

C. If AEB does not pay the Purchase Price for the Remaining Shares on or before December 30, 2008, AEB shall be in default and, in addition to all other rights and remedies of TIC, default interest shall begin accruing on the Purchase Price for the Remaining Shares as of January 1, 2008 at an annual rate of eighteen percent (18%) until the Purchase Price for the Remaining Shares (including all accrued interest) is paid in full. AEB acknowledges that remedies at law may be inadequate to protect TIC against the failure of AEB to perform under the terms of this Agreement and, without prejudice to any other rights and remedies otherwise available, AEB agrees to the granting of equitable relief, including injunctive relief and specific performance, in favor of TIC for purpose of enforcing this Agreement and without proof of actual damages.

2.0

General Releases

2.1

Termination of Alliance and Services Agreement. The Parties acknowledge and agree that both the Alliance Agreement and the Services Agreement have been terminated and no further liabilities, obligations or duties exist thereunder on behalf of either Party.



2



2.2

AEB on its own behalf and on behalf of its corporate parents, subsidiaries, affiliates, successors, predecessors, assigns, agents, employees, principals, owners, representatives, officers and directors, hereby waive and release all rights, claims, demands, costs, expenses, liabilities, lawsuits, losses, payments, debts and causes of action, whether known or unknown, and whether existing now or at any time prior to the Effective Date of this Agreement, and whether arising in contract, tort or otherwise, against TIC and its parents, subsidiaries, affiliates, successors, predecessors, assigns, agents, employees, attorneys, representatives, officers and directors arising from or relating to the Alliance Agreement, the Services Agreement or any services TIC provided to or was to have provided to AEB.

2.3

TIC on its own behalf and on behalf of its corporate parents, subsidiaries, affiliates, successors, predecessors, assigns, agents, employees, principals, owners, representatives, officers and directors, hereby waives and releases all rights, claims, demands, costs, expenses, liabilities, lawsuits, losses, payments, debts and causes of action, whether known or unknown, and whether existing now or at any time prior to the Effective Date of this Agreement, and whether arising in contract, tort or otherwise, against AEB and their respective parents, subsidiaries, affiliates, successors, predecessors, assigns, agents, employees, principals, owners, attorneys, representatives, officers and directors arising from or relating to the Alliance Agreement, the Services Agreement, or any obligations owed by AEB to TIC.

2.4

Notwithstanding the terms of this Section 2.0, no provision of this Agreement shall waive or release or shall be construed to waive or release the rights, duties, obligations, representations and warranties created by or arising out of this Agreement.

3.0

Warranties and Representations

3.1

AEB makes the following warranties and representations to and for the benefit of TIC:

A.

AEB is a corporation validly existing and in good standing under the laws of its jurisdiction of incorporation.

B.

AEB has all requisite corporate power and authority to enter into, deliver and perform this Agreement and to consummate the transactions contemplated herein. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated herein, have been, or will be, duly authorized by all necessary corporate action. This Agreement has been duly executed and delivered by AEB and constitutes its valid and legally binding obligation, enforceable in accordance with its terms.

C.

No approval, order, consent of or filing with any governmental authority is required on the part of AEB, in connection with the execution, delivery and performance of this Agreement or any other documents and agreements to be delivered under this Agreement or the performance of AEB’s obligations under this Agreement or any other documents and agreements to be delivered under this Agreement.



3



3.2

TIC makes the following warranties and representations to and for the benefit of AEB:

A.

TIC is a corporation validly existing and in good standing under the laws of its jurisdiction of incorporation.

B.

TIC has all requisite corporate power and authority to enter into, deliver and perform this Agreement and to consummate the transactions contemplated herein. The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated herein, have been, or will be at Closing, duly authorized by all necessary corporate action. This Agreement has been duly executed and delivered by TIC and constitutes its valid and legally binding obligation, enforceable against TIC in accordance with its terms.

C.

No approval, order, consent of or filing with any governmental authority is required on the part of TIC, in connection with the execution, delivery and performance of this Agreement or any other documents and agreements to be delivered under this Agreement or the performance of the TIC’s obligations under this Agreement or any other documents and agreements to be delivered under this Agreement.

4.0

Miscellaneous

4.1

This Agreement shall be governed and controlled by the laws of the State of California, without giving effect to its conflict of law principles and each party irrevocably and unconditionally submits to the exclusive jurisdiction of the courts of the State of California and all courts competent to hear appeals therefrom.

4.2

Each Party acknowledges that it has read this Agreement, has participated in its negotiation, understands its contents, and has had the opportunity to consult with legal counsel concerning this Agreement, and further agrees that this Agreement shall not be construed more strictly against one Party.

4.3

The Parties agree that this Agreement is a compromise and settlement of disputed claims and shall not be deemed or construed to be an admission regarding any Party’s claims.

4.4

The illegality or unenforceability of any provision or any part of any provision of this Agreement as determined by a court of competent jurisdiction shall not affect or impair the validity, legality or enforceability of any other provision or part of this Agreement.

4.5

This Agreement sets forth the entire agreement of the Parties regarding the subject matter hereof and supercedes any and all prior agreements or understandings between the Parties regarding the subject matter hereof. This Agreement may not be amended, cancelled, revoked or otherwise modified except by a written agreement signed by both of the Parties.

4.6

The Parties agree that the terms of this Agreement shall remain confidential, and neither Party shall make any disclosure of its terms and conditions to any third party or entity, other than for accounting, tax, financing, insurance and surety review purposes, or as may be



4



required by law; or unless a Party seeks to enforce this Agreement because of a claimed breach hereof. Nothing in this paragraph, however, shall prohibit the Parties from disclosing that disputes existing between them have been settled. The parties acknowledge that AEB is legally required to disclose material aspects of this Agreement in its public filings with the Securities and Exchange Commission.

4.7

Each Party warrants that it has not assigned any rights or obligations under the Alliance Agreement or Services Agreement and that it has full power and authority to enter into and execute this Agreement.

4.8

This Agreement shall be binding upon, shall inure to the benefit of and shall be enforceable by, each of the Parties and their respective agents, heirs, employees, affiliates, successors and assigns.

4.9

The terms of this Agreement shall be specifically enforceable by the Parties. Should either party employ an attorney or attorneys to enforce any of the provisions hereof or of any instrument or document given or delivered pursuant to this Agreement, or to protect its interest in any matter arising under this Agreement or any instrument or document given or delivered pursuant to this Agreement, or to recover damages for the breach of this Agreement or any instrument or document given or delivered pursuant to this Agreement or to seek specific performance of this Agreement, the nonprevailing party in any action pursued in courts of competent jurisdiction agrees to pay the prevailing party all reasonable costs, damages and expenses, including attorneys’ fees and court costs and costs of discovery and paralegals, expended or incurred in connection therewith.

4.10

This Agreement may be executed in counterparts, but shall not be and become effective until signed by both Parties on one or more counterparts. When all counterparts have been executed, they shall have the same effect as if the Parties had executed a single instrument. Transmission of an executed counterpart of this instrument by telecopier or by electronic pdf file shall be deemed to constitute due and sufficient delivery of such counterpart.

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.

 

 

 

TIC - THE INDUSTRIAL COMPANY

 

AE BIOFUELS, INC.

[EXHIBIT1012002.GIF]

- President/CEO

 

[EXHIBIT1012004.GIF]

By: (signature and title)

 

By: (signature and title)

 

 

 

[EXHIBIT1012006.GIF]

 

[EXHIBIT1012008.GIF]

Printed Name

 

Printed Name

 

 

 

 

 

Chairman/CEO



5



Exhibit A
To
Agreement and
Mutual Waiver and Release
(Stock Assignment)

STOCK ASSIGNMENT AND POWER

FOR GOOD AND VALUABLE CONSIDERATION, the receipt and sufficiency of which are hereby acknowledged, TIC – The Industrial Company, a Delaware corporation (“ Assignor ”) does hereby sell, transfer, convey and assign unto ___________________________ (“ Assignee ”), all of Assignor’s right, title and interest in and to _______________________ (________) shares of capital stock (the “ Stock ”) of AE Biofuels, Inc., a Nevada corporation (the “ Corporation ”).

Assignor does hereby irrevocably appoint the Secretary of the Corporation as attorney-in-fact to transfer the Stock on the books and records of the Corporation with full power of substitution in the premises.

IN WITNESS WHEREOF, this Stock Assignment Power is executed by Assignor as of _________________, 2008.

 

 

 

ASSIGNOR:

 

 

 

TIC – The Industrial Company

 

 

 

By:

 

 

 

 

 

Title:

 

 




6


EXHIBIT 3.1.1

[EXHIBITX311002.GIF]

ROSS MILLER
Secretary of State
204 North Carson Street, Ste 1
Carson City, Nevada 89701-4299
(776) 684 5708
Website: secretaryofstate.biz


 

 

Filed in the office of

Document Number

 

 

[EXHIBITX311004.GIF]

20070693762-42

 

 

Filing Date and Time

Certificate of Amendment

 

Ross Miller

10/11/2007 10:00 AM

(PURSUANT TO NRS 78.385 AND 78.390)

 

Secretary of State

Entity Number

 

 

State of Nevada

E0784312006-4

 

 

 

 


USE BLACK PEN ONLY - DO NOT HIGHLIGHT

 

ABOVE SPACE IS FOR OFFICE USE ONLY

Certificate of Amendment to Articles of Incorporation
For Nevada Profit Corporations
(Pursuant to NRS 78.385 and 78.390 - After Issuance of Stock)

1. Name of corporation:

 

MARWICH II, LTD.

 

2. The articles have been amended as follows (provide article numbers, if available):

 

The first two sentences of Article 9 of the Articles of Incorporation are amended to read as follows, but the remainder of the paragraph comprising Article 9 shall remain unchanged:

 

Article 9. CLASSIFICATION OF CAPITAL STOCK. The Corporation is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and “Preferred Stock.” The total number of shares which the Corporation is authorized to issue is Four Hundred Sixty-Five Million shares, Four Hundred Million (400,000,000) shares of which shall be common Stock, $0.001 par value (the “Common Stock”), and Sixty-Five Million (65,000,000) shares of which shall be Preferred Stock, $0.001 par value (the “Preferred Stock”).

 

 

 

 

 

 


3. The vote by which the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be

required by the provisions of the* articles of incorporation have voted in favor of the amendment is:

unanimous


4. Effective date of filing (optional):

 

 

 

(must not be later than 90 days after the certificate is filed)

 

 

 

 

5. Officer Signature (Required):

X

[EXHIBITX311006.GIF]

 

* If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote, in addition to the affirmative vote otherwise required, of the holders of shares, representing a majority of the voting power of each class or series affected by the amendment regardless of limitations or restrictions on the voting power thereof.

IMPORTANT: Failure to include any of the above information and submit the proper fees may cause this filing to be rejected.

This form must be accompanied by appropriate fees.

Nevada Secretary of State Amend Pofit-After)

 

Revised on 01/01/07




EXHIBIT 31.1

 

CERTIFICATIONS

 

I, Eric A. McAfee, certify that:

 

1.   I have reviewed this quarterly report on Form 10-Q for the quarter ended September 30, 2008 of AE Biofuels, Inc.;

 

2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.   Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.   The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

 

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements, for external purposes in accordance with generally accepted accounting principles;

 

(c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.   The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: November 11, 2008

 

By:

/s/ Eric A. McAfee

 

Eric A. McAfee

Chief Executive Officer






EXHIBIT 31.2

 

CERTIFICATIONS

 

I, William J. Maender, certify that:

 

1.   I have reviewed this quarterly report on Form 10-Q for the quarter ended September 30, 2008 of AE Biofuels, Inc.;

 

2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.   Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.   The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

 

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements, for external purposes in accordance with generally accepted accounting principles;

 

(c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.   The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: November 13, 2008

 

By:

/s/ William J. Maender

 

William J. Maender

Chief Financial Officer






EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

 

AS ADOPTED PURSUANT TO SECTION 906 OF THE

 

SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of AE Biofuels, Inc. (the "Company") on Form 10-Q for the period ending September 30, 2008, as filed with the Securities and Exchange Commission on the date hereof (the " Report " ), I, Eric A. McAfee, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)   The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and

 

(2)   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

By:

/s/ Eric A. McAfee

 

Eric A. McAfee

Chief Executive Officer

Date: November 11, 2008





EXHIBIT 32.2

 

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

 

AS ADOPTED PURSUANT TO SECTION 906 OF THE

 

SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of AE Biofuels, Inc. (the "Company") on Form 10-Q for the period ending September 30, 2008, as filed with the Securities and Exchange Commission on the date hereof (the " Report " ), I, William J. Maender, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)   The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and

 

(2)   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

By:

/s/ William J. Maender

 

William J. Maender

Chief Financial Officer

Date: November 13, 2008